Difference between revisions of "2012 Group 5 Project"

From CellBiology
m (Protected "2012 Group 5 Project": Project deadline ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
(163 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
{{2012 Projects}} [[File:EMBO.JPG|550px|thumb|right|Figure 1. 30 Years of Wnt Signalling Conference]]
 
{{2012 Projects}} [[File:EMBO.JPG|550px|thumb|right|Figure 1. 30 Years of Wnt Signalling Conference]]
 +
  
 
=Wnt/β-catenin Signalling Pathway=
 
=Wnt/β-catenin Signalling Pathway=
 +
 +
2012 marks the 30th anniversary of the identification of Wnt-1, the first component of the Wnt signaling pathway to be discovered. Since this breakthrough, researchers from around the globe have extensively studied and pieced together the multiple components that form the Wnt signaling pathway as it is known and accepted today.
  
 
==Introduction==
 
==Introduction==
  
2012 marks the 30th anniversary of the identification of Wnt-1, the first component of the Wnt signaling pathway to be discovered. Since this breakthrough, researchers from around the globe have extensively studied and pieced together the multiple components that form the Wnt signaling pathway as it is known and accepted today.  
+
The classical pathway of Wnt signalling that is best understood in current research is the Wnt-catenin signalling pathway. This signal transduction pathway is evolutionarily conserved and features heavily in development, regeneration, stem cell regulation and cellular processes such as proliferation and migration<ref name=PMID17081971/>.
  
The classical pathway of Wnt signalling that is best understood in current research is the Wnt/β-catenin signalling pathway which features heavily in development, regeneration, stem cell regulation and cellular processes such as proliferation and migration<ref name=PMID17081971/>.
+
The term 'Wnt' was coined to reflect the [[#Glossary |'''homolog''']] genes: ''Wingless'' in Drosophila and ''Int-1'' in mammals. Wnt proteins encompass a network of secreted [[#Glossary |'''glycolipoproteins''']]<ref name=PMID17081971><pubmed>17081971</pubmed></ref>, forming the basis of this highly conserved pathway.  The various elements, [[#Glossary |'''agonists''']] and [[#Glossary |'''antagonists''']] of this pathway will be discussed, with key emphasis on the structure and function.  
 
 
Wnt proteins encompass a network of secreted ‘‘‘[[#GLOSSARY |glycolipoprotein]]’’’s<ref name=PMID17081971><pubmed>17081971</pubmed></ref>, forming the basis of this highly conserved pathway.  The various elements, ‘‘‘[[#GLOSSARY |agonist]]s’’’ and ‘‘‘[[#GLOSSARY |antagonist]]s’’’ of this pathway will be discussed, with key emphasis on the structure and function.  
 
  
 
Furthermore, mutations in components of this pathway have been associated with cancers, developmental defects and other diseases which will be discussed in further detail.  
 
Furthermore, mutations in components of this pathway have been associated with cancers, developmental defects and other diseases which will be discussed in further detail.  
  
It is important to note that the Wnt/β-catenin signalling pathway is becoming increasingly complex with the addition of new molecules being discovered in recent years. Areas of current research and future directions will also be outlined.  
+
It is important to note that the Wnt/β-catenin signalling pathway is becoming increasingly complex with the addition of new molecules being discovered in recent years. Areas of current research and future directions will also be outlined.
  
 
==History==
 
==History==
  
[[File:Beta_catenin.JPG|350px|thumb|right|Figure 2. Overall structure of the β-catenin/XAxin-CBD complex]]
+
{|  width="100%" cellspacing="1" cellpadding="1"<tbody>
 +
|  style="background:orange;" valign="top" | <b>Year</b>
 +
|  style="background:orange;" valign="top" | <b>Significant Discovery</b>
 +
|-
 +
|  valign="top" | '''1973'''
 +
|  valign="top" |
 +
* A mutant of ''Drosophila melanogaster'' which had no wings was characterised as ''Wingless (Wg)''  <ref>Sharma RP '''Wingless, a new mutant in D.melanogaster.''' Drosoph. Inf. Serv: 1973, 50;134 </ref>
 +
|-
 +
|  valign="top" | '''1982'''
 +
|  valign="top" |
 +
* Roel Nusse and Harold Varmus found that mouse mammary tumour virus ([[#Glossary |'''MMTV''']]) stimulated tumour formation when the ''Int1'' (integration 1) gene was activated.<ref><pubmed>6297757</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1987'''
 +
|  valign="top" |
 +
* Rijsewijk et al identifies the mammalian [[#Glossary |'''homolog''']] of the Drosophila ''Wingless'' gene as ''Int1.''<ref><pubmed>3111720</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1989'''
 +
|  valign="top" |
 +
* Screening of zygotic [[#Glossary |'''lethal mutations''']] in Drosophila identified new Wnt signalling molecules e.g. Dishevelled and Shaggy.<ref><pubmed>2499512</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1990'''
 +
|  valign="top" |
 +
* Riggleman et al reports on how the accumulation of Armadillo (mammalian [[#Glossary |'''homolog''']] is beta-catenin) in Drosophila is posttranscriptionally  controlled by the Wingless gene.<ref name="PMID2225066"><pubmed>2225066</pubmed></ref>
 +
* Through nucleotide sequence analysis and peptide mapping, [[#Glossary |'''APC''']]  was found to associated with β-catenin<ref><pubmed>8259518</pubmed></ref><ref><pubmed>8259519</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1991'''
 +
|  valign="top" |
 +
* The nomenclature of Wingless and Int-1 was combined to form the mnemonic,'' Wnt''<ref><pubmed>1846319</pubmed></ref>.
 +
* Molecular cloning of β-catenin<ref><pubmed>1962194</pubmed></ref>, [[#Glossary |'''LEF''']]  (lymphoid enhancer factor)<ref name="PMID2225066"/> and [[#Glossary |'''TCF''']]  (T-cell factor)<ref><pubmed>1989880</pubmed></ref> transcription factors was conducted.
 +
|-
 +
|  valign="top" | '''1992'''
 +
|  valign="top" |
 +
* Wingless signaling was discovered to be regulated by zeste-white 3 (also called Shaggy), which is the Drosophila [[#Glossary |'''homolog''']] of mammalian Glycogen Synthase Kinase-3 ([[#Glossary |'''GSK ''']]-3).<ref><pubmed>1335365</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1994'''
 +
|  valign="top" |
 +
* Mutations in Dishevelled affected phenotype and  gene expression, indicating its crucial role in the Wnt signalling pathway<ref><pubmed>7906389</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1995'''
 +
|  valign="top" |
 +
* [[#Glossary |'''APC''']]  is involved in the degradation of β-catenin and hence regulates its cytoplasmic levels<ref name="PMID7708772"><pubmed>7708772</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1996'''
 +
|  valign="top" |
 +
* The interaction of β-catenin with the transcription factors [[#Glossary |'''LEF''']] and [[#Glossary |'''TCF''']]  was discovered<ref><pubmed>8757136</pubmed></ref>
 +
* Bhanot et al identifies Frizzled as a receptor for Wnt [[#Glossary |'''ligands''']]<ref><pubmed>8717036</pubmed></ref>
 +
* A transmembrane protein identified as Porcupine was found to be involved in the processing of Wnt [[#Glossary |'''ligands''']]<ref><pubmed>8985181</pubmed></ref>
 +
* β-catenin levels were reported to be three times higher in tumour tissues than in normal specimens, indicating the link between β-catenin accumulation and colorectal cancers<ref><pubmed>8616874</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1997'''
 +
|  valign="top" |
 +
* Huber et al investigates the three dimensional structure of β-catenin<ref><pubmed>9298899</pubmed></ref>.
 +
* Phosphorylation of β-catenin by GSK3β (in the absence of Wnt) signals degradation via ubiquitin/[[#Glossary |'''proteasome''']]<ref><pubmed>9233789</pubmed></ref>.
 +
* The gene expression of the [[#Glossary |'''homeotic gene''']] Ubx is discovered to be controlled by Wnt signalling, thus implicating Ubx as the first Wnt target gene<ref><pubmed>9118221</pubmed></ref>
 +
|-
 +
|  valign="top" | '''1998'''
 +
|  valign="top" |
 +
* Axin-1 and Axin-2 were found to be important components of the 'destruction complex' ([[#Glossary |'''GSK ''']]3β and [[#Glossary |'''APC''']]) and promoted the phosphorylation of β–catenin<ref name="PMID9554852"><pubmed>9554852</pubmed></ref><ref><pubmed>9601644</pubmed></ref> 
 +
|-
 +
|  valign="top" | '''1999'''
 +
|  valign="top" |
 +
* Peters et al identifies the function of Casein kinase 1 ([[#Glossary |'''CK1''']]) in increasing the phosphorylation of [[#Glossary |'''LRP''']], boosting its ability to recruit Axin<ref><pubmed>10517632</pubmed></ref>.
 +
* Protein phosphatase ([[#Glossary |'''PP2A''']]) is involved in the regulation of [[#Glossary |'''GSK''']]3β-dependent phosphorylation of β–catenin<ref><pubmed>9920888</pubmed></ref><ref><pubmed>10092233</pubmed></ref>     
 +
|-
 +
|  valign="top" | '''2000'''
 +
|  valign="top" |
 +
* Graham et al determines the 3D crystal structure of the β-catenin–[[#Glossary |'''TCF''']] complex<ref><pubmed>11136974</pubmed></ref>.
 +
*  Low-density lipoprotein receptor-related proteins ([[#Glossary |'''LRP''']]) such as [[#Glossary |'''LRP''']]-5 and [[#Glossary |'''LRP''']]-6 interact with Wnt proteins and function as coreceptors of the [[#Glossary |'''Fz''']] receptor<ref><pubmed>11029007</pubmed></ref>
 +
|-
 +
|  valign="top" | '''2001'''
 +
|  valign="top" |
 +
* Wnt protein interacts with [[#Glossary |'''LRP''']]-5 and enhances the binding of axin to the intracellular domain of [[#Glossary |'''LRP''']]-5<ref name="PMID11336703"><pubmed>11336703</pubmed></ref>
 +
|-
 +
|  valign="top" | '''2003'''
 +
|  valign="top" |
 +
* An alternate Wnt receptor, besides [[#Glossary |'''Fz''']], was recognised as Derailed in Drosophila (RYK in mammals)<ref><pubmed>12660735</pubmed></ref>.
 +
* Xing et al determines the crystal structure of the β-catenin/Axin complex and investigates the structural interactions between them<ref><pubmed>14600025</pubmed></ref>
 +
|-
 +
|  valign="top" | '''2006'''
 +
|  valign="top" |
 +
* [[#Glossary |'''Caveolin''']] is involved in internalising the [[#Glossary |'''LRP''']]-6 receptor and inhibits the binding of β-catenin to Axin<ref><pubmed>16890161</pubmed></ref>
 +
|-
 +
|  valign="top" | '''2007'''
 +
|  valign="top" |
 +
* Dishevelled polymerises when recruited to the plasma membrane, allowing it to act as a scaffold for other interactions<ref><pubmed>17549080</pubmed></ref>
 +
|-
 +
|  valign="top" | '''2008'''
 +
|  valign="top" |
 +
* Using an [[#Glossary |'''siRNA''']] screen, Major et al identified AGGF1 as a chromatin associated protein that involved in regulating β-catenin mediated transcription<ref><pubmed>19001663</pubmed></ref>
 +
|-
 +
|  valign="top" | '''2010'''
 +
|  valign="top" |
 +
* A mediator of Hippo signalling known as TAZ inhibits Wnt signalling by binding to Dishevelled<ref><pubmed>20412773</pubmed></ref>
 +
|}
 +
 
 +
==Key players in Wnt/β-catenin signalling==
 +
 
 +
This table provides an introduction to the various proteins involved in what would be a complex interaction in the Wnt/β-catenin signalling pathway. It is aimed to simplify the following mechanisms of action by elucidating the characteristics of each protein. For each protein listed, the gene from which it is derived is given in brackets, followed by a column providing an illustration to help the reader better picture the respective protein. The general function and antagonists are also outlined for reference.
 +
 
 +
{| border="1" cellpadding="5"
 +
|-style="background:Orange" align="center"
 +
! Protein (Gene)
 +
! Diagram
 +
! width="250"|Structure
 +
! width="450"|Function
 +
! width="450"|Inhibitors
 +
|-
 +
| align="center" | '''Wnt''' (WNT)
 +
| align="center" width="150px" | [[File:Genomic_structure_and_localization_of_WNT-4.JPG|250px]]
 +
| align="center" | Evolutionarily conserved protein across species.<ref name="PMID9407023"><pubmed>9407023</pubmed></ref> Most Wnt proteins figure in the region of 40 kDa, each possessing a characteristic 23 or 24 cysteine residues highly conserved in their spacing. This suggests that the formation of [[#Glossary |'''disulfide bonds''']] plays a significant role in determining tertiary protein structure<ref name="PMID11806834"><pubmed>11806834</pubmed></ref>
 +
| align="center" | Initiates Wnt signalling when it binds as a [[#Glossary |'''ligand''']] to the [[#Glossary |'''Fz''']] receptor with [[#Glossary |'''LRP''']]<ref name="PMID9312064"/> and destabilises the β-catenin degradation complex, dephosphorylating β-catenin and subsequently enabling its migration and accumulation in the cell nucleus for gene transcription <ref name="PMID12781368"><pubmed>12781368</pubmed></ref>
 +
|
 +
*The FRP family resembles the Wnt-interacting domain of [[#Glossary |'''Fz''']] receptors, thus competitively [[#Glossary |'''sequesters''']] Wnt from the [[#Glossary |'''Fz''']] receptor<ref><pubmed>9118212</pubmed></ref>.
 +
*WIF-1 has been shown to competitively antagonise Wnt binding to the [[#Glossary |'''Fz''']] receptor <ref><pubmed>10201374</pubmed></ref>
 +
*Cerberus is a secreted protein that directly binds to the Wnt protein and inhibits signal transduction <ref><pubmed>10067895</pubmed></ref>
 +
*Dkk indirectly inhibits Wnt protein signalling by binding to the co-receptor [[#Glossary |'''LRP''']]-6, thus making it unable to bind to Wnt for [[#Glossary |'''Fz''']] signal transduction <ref name="PMID11357136"><pubmed>11357136</pubmed></ref>
 +
* The extracellular sFRP family of proteins possess a consensus [[#Glossary |'''CRD''']] sequence on their [[#Glossary |'''N-terminus''']], with which they directly bind to Wnt, and prevent its association with [[#Glossary |'''Fz''']] receptors, thus antagonising the signal conduction <ref><pubmed>9096311</pubmed></ref>
 +
*Experiments suggest that axin indirectly blocks Wnt signalling, in a manner that renders further increases in Wnt levels ineffective <ref name="PMID9230313"><pubmed>9230313</pubmed></ref> 
 +
|-
 +
| align="center" | [[#Glossary |'''Fz''']](FZD)
 +
| align="center" width="150px" | [[File:Frizzled.JPG|150px]]
 +
| align="center" | [[#Glossary |'''Fz''']] houses a [[#Glossary |'''CRD''']] on the [[#Glossary |'''N-terminus''']], seven transmembrane domains, and a [[#Glossary |'''PDZ domain''']] on the [[#Glossary |'''C-terminus''']]<ref name="PMID11806834"/>
 +
| align="center" | Binds the Wnt [[#Glossary |'''ligand''']] at the extracellular [[#Glossary |'''N-terminus''']] for the initiation of the Wnt/β-catenin signalling pathway<ref name="PMID11806834"/>
 +
|
 +
*For inhibitors of the Fz receptor, refer to "Inhibitors" under '''Wnt'''
 +
|-
 +
| align="center" | [[#Glossary |'''LRP''']]-5/6 (LRP)
 +
| align="center" width="150px" | [[File:LRP6_active_sites.JPG|250px]]
 +
| align="center" | A protein that spans multiple domains. The extracellular component is comprised of four EGF-like repeats on the [[#Glossary |'''N-terminus''']]<ref name="PMID11357136"/>
 +
| align="center" | Co-receptor to the Wnt [[#Glossary |'''ligand''']] in its interaction with the [[#Glossary |'''Fz''']] receptor in signal transduction<ref><pubmed>11029008</pubmed></ref>. Causes translocation and association of axin to its intracellular tail, thus destabilising the β-catenin binding activity of axin<ref name=PMID11336703/>
 +
|
 +
* Dkk antagonises [[#Glossary |'''LRP''']]-5/6 binding to Wnt through competitive binding<ref name="PMID11357136"/> and complexes with the transmembrane protein Kremen2 for intracellular removal cell through endocytosis<ref><pubmed>12050670</pubmed></ref>
 +
|-
 +
| align="center" | [[#Glossary |'''Dsh''']] (DVL)
 +
| align="center" width="150px" | [[File:Dis.JPG|250px]]
 +
| align="center" | A phosphoprotein <ref name="PMID8288125"><pubmed>8288125</pubmed></ref> approximately 670 amino acids long <ref name="PMID8817329"><pubmed>8817329</pubmed></ref>. Possesses a  [[#Glossary |'''DIX''']] domain, which is thought to facilitate interaction with Axin <ref name="PMID9920888"><pubmed>9920888</pubmed></ref>.
 +
| align="center" | Prevents phosphorylatory activity of [[#Glossary |'''GSK-3β''']] upon hyperphosphorylation by the Wnt/[[#Glossary|'''LRP''']]-5/6 complex binding to the [[#Glossary |'''Fz''']] receptor<ref name="PMID7744250"><pubmed>7744250</pubmed></ref>, thus preventing β-catenin ubiquitination and degradation, to promote translocation into the nucleus.
 +
|
 +
* [[#Glossary |'''Nkd''']] blocks feedback signalling, thus inhibiting [[#Glossary |'''Dsh''']]<ref><pubmed>11752446</pubmed></ref>
 +
* [[#Glossary |'''Stbm''']] binds to and jointly immunoprecipitates [[#Glossary |'''Dsh''']]<ref><pubmed>12756182</pubmed></ref>
 +
* Dapper antagonises [[#Glossary |'''Dsh''']] in complex with Axin, [[#Glossary |'''GSK-3β''']], CK-I and β-catenin, leading to degradation of β-catenin and subsequent reduced signalling<ref><pubmed>11970895</pubmed></ref>
 +
* [[#Glossary |'''PKC''']], a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits [[#Glossary |'''Dsh''']] through phosphorylation, preventing β-catenin nuclear translocation<ref name="PMID11472835"><pubmed>11472835</pubmed></ref>
 +
*Experiments suggest that axin indirectly blocks [[#Glossary |'''Dsh''']] function, in a manner that renders further increases in [[#Glossary |'''Dsh''']] levels ineffective <ref name="PMID9230313"/>
 +
|-
 +
| align="center" | '''Axin''' (AXIN)
 +
| align="center" width="150px" | [[File:Axin_family_of_proteins.JPG|250px]]
 +
| align="center" | A 95.635 kDa protein<ref>Cell Signalling Technology. (2012). '''Axin 1 (human)'''. http://www.phosphosite.org/proteinAction.do?id=4768</ref>. Possesses a [[#Glossary |'''DIX''']] domain, which is thought to facilitate interaction with [[#Glossary |'''Dsh''']] <ref><pubmed>9920888</pubmed></ref>.
 +
| align="center" | In the absence of Wnt signalling, it constitutes the β-catenin ubiquitination complex along with [[#Glossary |'''APC''']] and [[#Glossary |'''GSK-3β''']]<ref name="PMID9312064"/> and its role as a [[#Glossary |'''scaffolding protein''']] enhances [[#Glossary |'''GSK-3β''']] phosphorylation of β-catenin<ref name="PMID9482734"><pubmed>9482734</pubmed></ref>
 +
|
 +
*the antibiotic [[#Glossary |'''LMB''']] prevents nuclear shuttling by blocking the  [[#Glossary |'''NES''']]- [[#Glossary |'''CRM1''']] interaction
 +
*Wnt downregulates axin through increased [[#Glossary |'''Dsh''']] expression, hindering axin phosphorylation by GSK-3β, leading to decreased stability and ultimately a shorter half-life<ref><pubmed>10196136</pubmed></ref>
 +
|-
 +
| align="center" | [[#Glossary |'''GSK-3β''']](GSK3β)
 +
| align="center" width="150px" | [[File:GSK.JPG|250px]]
 +
| align="center" | 46 kDa kinase <ref>National Center for Biotechnology Information, U.S. National Library of Medicine. (2002). '''Glycogen synthase kinase-3 beta''' http://www.ncbi.nlm.nih.gov/protein/P49841.2</ref>. Possesses a surface channel on the hydrophobic C-terminal helical domain that binds a 19 amino acid residue on Axin <ref name="PMID12554650"><pubmed>12554650</pubmed></ref>.
 +
| align="center" | Constitutes the β-catenin ubiquitination complex along with axin and [[#Glossary |'''APC''']]<ref name="PMID9312064"/>; its primary role in the Wnt/β-catenin signalling pathway is inhibition of β-catenin nuclear translocation through phosphorylation of three amino acids at the [[#Glossary |'''N-terminus''']]<ref><pubmed>12027456</pubmed></ref> after priming by [[#Glossary |'''CK-I''']]<ref name="PMID12000790"><pubmed>12000790</pubmed></ref>, for subsequent ubiquitination and degradation by the [[#Glossary |'''proteasome''']]. This activity is enhanced by [[#Glossary |'''GSK-3β''']] phosphorylation of axin<ref name="PMID9482734"/> and [[#Glossary |'''APC''']]<ref><pubmed>8638126</pubmed></ref> which appears to promote phosphorylation of β-catenin by [[#Glossary |'''GSK-3β''']] in the complex.
 +
|
 +
* Frat1, which appears to be recruited by [[#Glossary |'''Dsh''']] in complex, tightly binds GSK-3β even after complex dissociation and β-catenin degradation<ref><pubmed>10428961</pubmed></ref>
 +
* [[#Glossary |'''PKC''']] inhibits [[#Glossary |'''GSK-3β''']] phosphorylatory activity<ref><pubmed>8887544</pubmed></ref>
 +
|-
 +
| align="center" | '''Diversin''' (ANKRD6)
 +
| align="center" | [[File:Diversin.JPG|250px]]
 +
| align="center" | 776 amino acid with multiple ankyrin repeat domains <ref name="PMID12454917"><pubmed>12454917</pubmed></ref>.
 +
| align="center" | Primes β-catenin for degradation by recruiting CK-I to phosphorylate serine 45 on the [[#Glossary |'''N-terminus''']] before subsequent phosphorylation of threonine 41, serine 37 and serine 33 by GSK-3β and degradation by E3 ubiquitin ligase β-TrCP<ref name="PMID12000790"/>
 +
| There are no known inhibitors of Diversin in the published literature.
 +
|-
 +
| align="center" | [[#Glossary |'''APC''']] (APC)
 +
| align="center" width="150px" | [[File:APC.JPG|150px]]
 +
| align="center" | A large 312 kDa protein <ref>National Center for Biotechnology Information, U.S. National Library of Medicine. '''Adenomatous Polyposis Coli (Xenopus laevis)'''. http://www.ncbi.nlm.nih.gov/protein/AAB41671.1</ref>. Possesses a 25 amino acid SAMP repeat that is sufficient for full Axin binding  <ref name="PMID10811618"><pubmed>10811618</pubmed></ref>
 +
| align="center" | Possesses a numerous and varied set of roles ranging from cell migration and adhesion, cell cycle regulation and chromosome stability<ref><pubmed>11978510</pubmed></ref>. In the Wnt/β-catenin signalling pathway, [[#Glossary |'''APC''']] constitutes the β-catenin ubiquitination complex along with axin and [[#Glossary |'''GSK-3β''']]<ref name="PMID9312064"/>. It binds to axin via [[#Glossary |'''SAMP''']] elements<ref name=PMID9554852/>, and to β-catenin via three 15-amino acid repeats and seven 20-amino acid repeats<ref><pubmed>10526234</pubmed></ref>
 +
|
 +
*APC is itself an inhibitor of the β-catenin. For inhibitors of APC in the Wnt/β-catenin signalling pathway, refer to "Inhibitors" under '''Axin'''
 +
|-
 +
| align="center" | '''β-catenin''' (CTNNB1)
 +
| align="center" width="150px" | [[File:Murine_bcat.jpg|250px]]
 +
| align="center" | The [[#Glossary |'''N-terminus''']] accommodates a critical sequence of thirteen armadillo repeats that competitively bind E-cadherin, [[#Glossary |'''LEF''']]-1 and [[#Glossary |'''APC''']]<ref name="PMID10966653"><pubmed>10966653</pubmed></ref>. The [[#Glossary |'''C-terminus''']] houses a glycine-rich transactivation domain<ref name="PMID9118222"><pubmed>9118222</pubmed></ref>
 +
| align="center" | Involved in mediating both [[#Glossary |'''morphogenesis''']] and maintenance of tissue integrity in the endothelium, bound to a-catenin that subsequently binds to the actin cytoskeleton. Gene expression is mediated in conjunction with [[#Glossary |'''TCF''']] /[[#Glossary |'''LEF''']], upon translocation from the cytosol into the nucleus<ref name="PMID10966653"/>
 +
| The axin/[[#Glossary |'''APC''']]/GSK-β complex phosphorylates β-catenin and marks it for ubiquitination and degradation by the [[#Glossary |'''proteasome''']]<ref name="PMID12781368"/>
 +
|-
 +
| align="center" | [[#Glossary |'''TCF''']] /[[#Glossary |'''LEF''']] (TCF7/LEF)
 +
| align="center" width="150px" | [[File:Protein_structure_LEF1_TCF4_TCF3.JPG|250px]]
 +
| align="center" | The [[#Glossary |'''N-terminus''']] constitutes the β-catenin interaction domain; [[#Glossary |'''TCF''']] /[[#Glossary |'''LEF''']] also possesses a [[#Glossary |'''HMG''']] box DNA-binding domain<ref name="PMID9118222"/>
 +
| align="center" | Mediates DNA binding when in complex with β-catenin; the [[#Glossary |'''N-terminus''']] of [[#Glossary |'''TCF''']] /[[#Glossary |'''LEF''']] associates with the β-catenin [[#Glossary |'''C-terminus''']]<ref name="PMID9118222"/>
 +
|
 +
* [[#Glossary |'''CAMKII''']], a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits [[#Glossary |'''LEF''']] downstream of β-catenin, acting at the transcription factor complex level<ref name="PMID11472835"/>
 +
|}
  
'''1973:''' A mutant of ''Drosophila melanogaster'' which had no wings was characterised as ''Wingless (Wg)''  <ref>Sharma RP '''Wingless, a new mutant in D.melanogaster.''' Drosoph. Inf. Serv: 1973, 50;134 </ref>
+
==Normal function: Roles of Wnt/β-catenin signalling==
  
'''1982:''' Roel Nusse and Harold Varmus found that mouse mammary tumour virus (MMTV) stimulated tumour formation when the ''Int1'' (integration 1) gene was activated.<ref><pubmed>6297757</pubmed></ref>
+
===Embryonic development===
  
'''1987:''' Rijsewijk et al identifies the mammalian ‘‘‘[[#GLOSSARY |homolog]]’’’ of the Drosophila ''Wingless'' gene as ''Int1.''<ref><pubmed>3111720</pubmed></ref>
+
[[File:Wnt.JPG|150px|thumb|right|Figure 2. Stem cell markers (red and green) in neural crest stem cells cultured with Wnt]]
  
'''1989:''' Screening of zygotic ‘‘‘[[#GLOSSARY |lethal mutation]]’’’s in Drosophila identified new Wnt signalling molecules e.g. Dishevelled and Shaggy.<ref><pubmed>2499512</pubmed></ref>
+
The Wnt/β-catenin signaling pathway has been implicated as an important pathway in human fetal development. Through immunohistochemical staining, Eberhart and Argani (2001) localised nuclear beta catenin in fetal lung, placenta, kidney, cartilage, capillaries, adrenal glands and skin. This indicates that Wnt signaling regulates the development of specific set of organs and tissues.<ref><pubmed>11441336</pubmed></ref> For example, Wnt genes such as Wnt4 regulate the conversion of mesenchyme to epithelial cells in kidney [[#Glossary |'''morphogenesis''']].
  
'''1990:''' Riggleman et al reports on how the accumulation of Armadillo (mammalian ‘‘‘[[#GLOSSARY |homolog]]’’’ is beta-catenin) in Drosophila is posttranscriptionally  controlled by the Wingless gene.<ref name="PMID2225066"><pubmed>2225066</pubmed></ref>  
+
In addition, Wnt/β-catenin signaling is also involved in maintaining the [[#Glossary |'''pluripotency''']] of human embryonic stem cells (hESCs). Wnt3a promotes the reprogramming of somatic cells to [[#Glossary |'''pluripotency''']] in conjunction with the classical transcription factors, Oct4, Sox2 and Nanog.<ref><pubmed>18682236</pubmed></ref> For example, Oct4 has the effect of repressing Wnt/β-catenin signaling in self renewing hESCs and is depressed during hESC [[#Glossary |'''differentiation''']]<ref><pubmed>22392999</pubmed></ref>. Hence, this suggests that Wnt/β-catenin signaling is involved in [[#Glossary |'''differentiation''']] rather than [[#Glossary |'''self renewal''']].
  
'''1991:''' The nomenclature of Wingless and Int-1 was combined to form the mnemonic,'' Wnt''.<ref><pubmed>1846319</pubmed></ref>     
+
===Adult tissue self renewal===
  
'''1991:''' Molecular cloning of β-catenin<ref><pubmed>1962194</pubmed></ref>, ‘‘‘[[#GLOSSARY |LEF]]’’’  (lymphoid enhancer factor)<ref name="PMID2225066"/> and ‘‘‘[[#GLOSSARY |TCF]]’’’  (T-cell factor)<ref><pubmed>1989880</pubmed></ref> transcription factors was conducted.
+
[[File:Crypt.JPG|150px|thumb|right|Figure 3. Crypt villous junction, indicating the location of the progenitor compartment]]
  
'''1992:''' Wingless signaling was discovered to be regulated by zeste-white 3 (also called Shaggy), which is the Drosophila ‘‘‘[[#GLOSSARY |homolog]]’’’ of mammalian Glycogen Synthase Kinase-3 (GSK-3).<ref><pubmed>1335365</pubmed></ref> 
+
Wnt/β-catenin signalling features in a great variety of processes during embryogenesis however the interesting concept to note about Wnt/β-catenin signalling is that it is heavily involved in adult tissue self renewal as well <ref name=PMID17081971/>. For example, in the gut, Wnt signaling is essential for the establishment of the progenitor compartment in an intestinal crypt <ref name=PMID17081971/>. This is further supported by Kuhnert et al (2004) who noted that the inhibition of Wnt signalling results in the loss of crypts<ref><pubmed>14695885</pubmed></ref>. This means Wnt provides the mitotic stimulus for the progenitor cells in the crypts to proliferate. 
 
 
'''1993:''' Through nucleotide sequence analysis and peptide mapping, ‘‘‘[[#GLOSSARY |APC]]’’’  was found to associated with β-catenin<ref><pubmed>8259518</pubmed></ref><ref><pubmed>8259519</pubmed></ref>      
 
  
'''1994:''' Mutations in Dishevelled affected phenotype and gene expression, indicating its crucial role in the Wnt signalling pathway<ref><pubmed>7906389</pubmed></ref>      
+
Wnt/β-catenin signalling is also involved in the self renewal of bone tissue where several mouse models established the importance of Wnt signaling in bone homeostasis<ref name=PMID17081971/>. For instance, Babij et al (2003) observed how mice with [[#Glossary |'''gain of function''']] mutations in [[#Glossary |'''LRP''']]-5 (in osteoblasts) results in increased bone density and osteoclast activation<ref><pubmed>12817748</pubmed></ref>. In contrast, Kato et al (2002) noted how a [[#Glossary |'''loss of function''']] in [[#Glossary |'''LRP''']]-5 lead to decreased bone mass and faulty osteoblast maturation<ref><pubmed>11956231</pubmed></ref>.  Hence, Wnt signalling plays an essential role in maintaining the maturation and proliferation of osteoblasts.
  
'''1995:''' ‘‘‘[[#GLOSSARY |APC]]’’’  is involved in the degradation of β-catenin and hence regulates its cytoplasmic levels<ref name="PMID7708772"><pubmed>7708772</pubmed></ref>
+
Other tissues involved in self renewal via Wnt signaling include hair follicles and the haematopoietic system<ref name=PMID17081971/>.
  
'''1996:''' The interaction of β-catenin with the transcription factors ‘‘‘[[#GLOSSARY |LEF]]’’’  and ‘‘‘[[#GLOSSARY |TCF]]’’’  was discovered<ref><pubmed>8757136</pubmed></ref>
+
===Migration===
  
'''1996:''' Bhanot et al identifies Frizzled as a receptor for Wnt ‘‘‘[[#GLOSSARY |ligand]]’’’s<ref><pubmed>8717036</pubmed></ref>
+
Muller et al (2002) investigated how Wnt/beta catenin signalling is involved in the stimulation of epithelial cell motility<ref><pubmed>12372345</pubmed></ref>. They discovered that when β-catenin was activated, it had the ability to induce epithelial migration in cell culture. Furthermore, the addition of growth factors enhanced the transcriptional activity of β-catenin and induced more migration than beta catenin alone<ref name=PMID12372345><pubmed>12372345</pubmed></ref>. This indicates evidence of [[#Glossary |'''synergism''']] between Wnt signalling pathways and growth factors, which is particularly relevant in cancers. As a result, the cooperation between Wnt signaling and growth factors are likely stimulators of tumour progression and possibly the capacity to migrate and metastasise<ref name=PMID12372345/>.
  
'''1996:''' A transmembrane protein identified as Porcupine was found to be involved in the processing of Wnt ‘‘‘[[#GLOSSARY |ligand]]’’’s<ref><pubmed>8985181</pubmed></ref>
+
[[File:Noncanon.jpg|200px|thumb|right|Figure 4. Comparison of canonical and non-canonical Wnt signaling]]
  
'''1996:''' β-catenin levels were reported to be three times higher in tumour tissues than in normal specimens, indicating the link between β-catenin accumulation and colorectal cancers<ref><pubmed>8616874</pubmed></ref>
+
===Comparison with non-canonical Wnt signalling===
  
'''1997:''' Huber et al investigates the three dimensional structure of β-catenin<ref><pubmed>9298899</pubmed></ref>  
+
Wnt/β-catenin signalling is commonly referred to as the canonical Wnt signalling pathway, and its function is primarily centered around the differentiation and proliferation of cells in adults and embryos. In contrast, the non-canonical Wnt signalling pathways include the Planar Cell Polarity (PCP) pathway and Wnt/Calcium pathways, and are involved in regulating cell polarity, neural migration and myogenesis<ref><pubmed>19737646</pubmed></ref>. Despite their differences in intracellular effectors and function, these pathways have been known to cross talk with each other, for example during axis formation in ''Xenopus''<ref><pubmed>15797385</pubmed></ref>
  
'''1997:''' Phosphorylation of β-catenin by GSK3β (in the absence of Wnt) signals degradation via ubiquitin/’‘‘[[#GLOSSARY |’’’proteasome]]’’’<ref><pubmed>9233789</pubmed></ref> 
+
==Normal function: Mechanism of action==
  
'''1997:''' Identification of the ‘‘‘[[#GLOSSARY |homeotic gene]]’’’ Ubx as the first Wnt target gene <ref><pubmed>9118221</pubmed></ref>  
+
β-catenin commonly exists as a subunit making up the cadherin protein complex, where it links E-cadherin to α-catenin<ref name=PMID7790378><pubmed>7790378</pubmed></ref>.  Cadherin proteins play an integral role in the formation of adhesion junctions between cells <ref name=PMID7790378/>, and β-catenin in particular acts to help anchor the actin cytoskeleton within the cell<ref name=PMID7790378/>. The β-catenin gene can be said to function as an [[#Glossary |'''oncogene''']] given that the promotion of transcription of Wnt target genes by β-catenin has been shown to be involved in the development of an array of cancers including basal cell carcinoma, colorectal cancer and breast cancer.<ref><pubmed>21173432</pubmed></ref><ref name="PMID22550094"><pubmed>22550094</pubmed></ref><ref><pubmed>18708403</pubmed></ref>
  
'''1998:''' Axin 1 and axin 2 were found to interact with β-catenin, GSK3β and ‘‘‘[[#GLOSSARY |APC]]’’’  and to promote GSK3β - dependent phosphorylation and degradation of β-catenin
+
===In the absence of Wnt (“off state”)===  
<ref name="PMID9554852"><pubmed>9554852</pubmed></ref> <ref><pubmed>9601644</pubmed></ref> 
 
  
'''1999:''' Casein kinase 1 (CK1) was found to regulate β-catenin function <ref><pubmed>10517632</pubmed></ref>   
+
[[File:Wntoff.JPG|300px|thumb|right|Figure 4. Wnt signalling in the "off" state]]
  
'''1999:''' Protein phosphatase 2A (PP2A) interacts with the β-catenin destruction complex and modulates GSK3β (Glycogen synthase kinase 3β) function <ref><pubmed>9920888</pubmed></ref><ref><pubmed>10092233</pubmed></ref> 
 
  
'''2000:''' The three-dimensional structure of the β-catenin–’‘‘[[#GLOSSARY |TCF]]’’’  complex was determined <ref><pubmed>11136974</pubmed></ref> 
+
'''1.''' No extracellular "Wnt signal"
  
'''2000:''' Arrow, ‘‘‘[[#GLOSSARY |LRP]]-5’’’ and ‘‘‘[[#GLOSSARY |LRP]]-6’’’ were identified as coreceptors of Frizzled <ref><pubmed>11029007</pubmed></ref>
 
  
'''2001:''' ‘‘‘[[#GLOSSARY |LRP]]-5’’’ was found to transduce Wnt signals by recruitment of axin to the plasma membrane <ref name="PMID11336703"><pubmed>11336703</pubmed></ref>
+
'''2.''' β-catenin targeted for proteosomal degradation by its incorporation into a “destruction complex” comprising:
 +
* Intracellular Axin, [[#Glossary |'''GSK-3β''']] (glycogen synthase kinase β) and [[#Glossary |'''APC''']] (Adenomatous polyposis coli – coded for by the [[#Glossary |'''APC''']] [[#Glossary |'''tumour suppressor gene''']])<ref name=PMID19619488><pubmed>19619488</pubmed></ref>
 +
  
'''2003:''' The tyrosine kinase receptor Derailed in Drosophila (RYK in mammals) was identified as an alternative Wnt receptor <ref><pubmed>12660735</pubmed></ref>  
+
'''3.''' [[#Glossary |'''APC''']] and axin assemble into a structural scaffold, allowing the phosphorylation of the N-terminal of β-catenin by the coordinated action of CK1 and [[#Glossary |'''GSK-3β''']]<ref><pubmed>11955436</pubmed></ref>
  
'''2006:''' ‘‘‘[[#GLOSSARY |LEF]]’’’  mutations were associated with sebaceous gland tumours in humans, showing that Wnt–β-catenin signalling is inhibited in these tumours <ref><pubmed>16565724</pubmed></ref>
 
  
'''2007:''' Dishevelled was found to polymerize at the plasma membrane and to recruit axin upon Wnt stimulation <ref name="PMID17529994"><pubmed>17529994</pubmed></ref>
+
'''4.''' β-catenin is recognised by E3 ligase β-Trcp, ubiquinated and subsequently degraded by the 26S proteosome <ref><pubmed>15084453</pubmed></ref><ref name="PMID9312064"><pubmed>9312064</pubmed></ref>  
  
==Mechanism of action==
 
  
* β-catenin commonly exists as a subunit making up the cadherin protein complex, where it links E-cadherin to α-catenin <ref name=PMID7790378><pubmed>7790378</pubmed></ref>
+
'''5.''' Level of β-catenin in the cytosol is low, and therefore does not reach the nucleus at a level sufficient enough to affect transcription
  
* Cadherin proteins play an integral role in the formation of adhesion junctions between cells <ref name=PMID7790378/>
 
  
* β-catenin also acts to help anchor the actin cytoskeleton within the cell <ref name=PMID7790378/>
+
'''6.''' No transcription of Wnt target genes
 +
* [[#Glossary |'''TCF''']]/[[#Glossary |'''LEF''']] proteins act as transcriptional [[#Glossary |'''repressors''']], binding to proteins of the TLE /Groucho family <ref><pubmed>20676368</pubmed></ref>
 +
* HDAC represses transcription via chromatin remodelling in the form of [[#Glossary |'''histone deacetylation''']]<ref><pubmed>10737769</pubmed></ref>
  
* The β-catenin gene can be said to function as an ‘‘‘[[#GLOSSARY |oncogene]]’’’ given that the promotion of transcription of Wnt target genes by β-catenin has been shown to be involved in the development of an array of cancers including basal cell carcinoma, colorectal cancer and breast cancer.<ref><pubmed>21173432</pubmed></ref><ref><pubmed>22550094</pubmed></ref><ref><pubmed>18708403</pubmed></ref>
 
  
===In the absence of Wnt (“off state”)===  
+
===In the presence of Wnt (“on state”)===
  
[[File:Wnt Signalling.jpg|350px|thumb|right|Figure 3. "Off" and "On" States of the Wnt/Beta-catenin Signalling Pathway]]
+
[[File:Wnton2.JPG|300px|thumb|right|Figure 5. Wnt signalling in the "on" state]]
  
* No extracellular "Wnt signal"
 
  
* β-catenin targeted for proteosomal degradation by its incorporation into a “destruction complex” comprising:
+
'''1.''' Extracellular “Wnt signal” binds to a cell surface G-protein coupled receptor of the “Frizzled” ([[#Glossary |'''FZ''']]) family
** Intracellular Axin, ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  (glycogen synthase kinase β) and ‘‘‘[[#GLOSSARY |APC]]’’’  (Adenomatous polyposis coli – coded for by the ‘‘‘[[#GLOSSARY |APC]]’’’  ‘‘‘[[#GLOSSARY |tumour suppressor gene]]’’’)<ref name=PMID19619488><pubmed>19619488</pubmed></ref>
 
 
* ‘‘‘[[#GLOSSARY |APC]]’’’  and axin assemble into a structural scaffold, allowing the phosphorylation of the N-terminal of β-catenin by the coordinated action of CK1 and ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  <ref><pubmed>11955436</pubmed></ref>
 
  
* β-catenin is recognised by E3 ligase β-Trcp, ubiquinated and subsequently degraded by the 26S proteosome <ref><pubmed>15084453</pubmed></ref><ref><pubmed>9312064</pubmed></ref>
 
  
* Level of β-catenin in the cytosol is low, and therefore does not reach the nucleus at a level sufficient enough to affect transcription
+
'''2.''' Low-density lipoprotein receptor-related protein ([[#Glossary |'''LRP''']]) family functions as a transmembrane co-receptor for [[#Glossary |'''FZ''']]
 +
* Recruitment of axin to the membrane where it is degraded upon initiation of the Wnt signalling cascade
 +
* Dissociation of β-catenin into the cytoplasm without degradation by the “destruction complex" <ref><pubmed>19279722</pubmed></ref><ref name="PMID9312064"/>
 +
  
* No transcription of Wnt target genes
+
'''3.''' Activation (phosphorylation and poly-ubiquination) of proteins of the “Dishevelled” ([[#Glossary |'''Dsh''']]) family
** ‘‘‘[[#GLOSSARY |TCF]]’’’ /’‘‘[[#GLOSSARY |LEF]]’’’  proteins act as transcriptional ‘‘‘[[#GLOSSARY |repressor]]’’’s, binding to proteins of the TLE /Groucho family <ref><pubmed>20676368</pubmed></ref>
+
* Implicated in the inactivation of the “destruction complex” by the recruitment of axin and [[#Glossary |'''GSK-3β''']] away from the complex <ref><pubmed>17529994</pubmed></ref>
** HDAC represses transcription via chromatin remodelling in the form of ‘‘‘[[#GLOSSARY |histone deacetylation]]’’’ <ref><pubmed>10737769</pubmed></ref>
 
  
===In the presence of Wnt (“on state”)===
 
  
* Extracellular “Wnt signal” binds to a cell surface G-protein coupled receptor of the “Frizzled” (FRZ) family
+
'''4.''' With the complex now interrupted, β-catenin resists ubiquination and reaches the nucleus in increased levels where it functions as a transcriptional enhancer alongside [[#Glossary |'''TCF''']]<ref name=PMID19619488/>
  
* Low-density lipoprotein receptor-related protein (‘‘‘[[#GLOSSARY |LRP]]’’’ ) family functions as a transmembrane co-receptor for FRZ
 
** Recruitment of axin to the membrane where it is degraded upon initiation of the Wnt signalling cascade
 
** Dissociation of β-catenin into the cytoplasm without degradation by the “destruction complex" <ref><pubmed>19279722</pubmed></ref><ref><pubmed>9312064</pubmed></ref>
 
 
* Activation (phosphorylation and poly-ubiquination) of proteins of the “Dishevelled” (‘‘‘[[#GLOSSARY |Dsh]]’’’ ) family
 
** Implicated in the inactivation of the “destruction complex” by the recruitment of axin and ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  away from the complex <ref><pubmed>17529994</pubmed></ref>
 
  
* With the complex now interrupted, β-catenin resists ubiquination and reaches the nucleus in increased levels where it functions as a transcriptional enhancer alongside ‘‘‘[[#GLOSSARY |TCF]]’’’  <ref name=PMID19619488/>
+
'''5.''' β-catenin directly competes with Groucho/TLEs for [[#Glossary |'''TCF''']] binding <ref><pubmed>19460168</pubmed></ref>
 +
* [[#Glossary |'''TCF''']] promotes binding of RNA polymerase to DNA template strand
  
*β-catenin directly competes with Groucho/TLEs for ‘‘‘[[#GLOSSARY |TCF]]’’’  binding <ref><pubmed>19460168</pubmed></ref>
 
  
* ‘‘‘[[#GLOSSARY |TCF]]’’’  promotes binding of RNA polymerase to DNA template strand
+
'''6.''' Induction of the downstream transcription of Wnt target genes, for example:
 +
* [[#Glossary |'''oncogenes''']] such as c-Myc and cyclin D1 involved in cell cycle control <ref name="PMID22466651"><pubmed>22466651</pubmed></ref>
 +
* MMP-7 and uPA, associated with [[#Glossary |'''metastasis''']] and the invasion of cancer cells <ref name="PMID22550094"/>
  
* Induction of the downstream transcription of Wnt target genes, for example:
+
[http://stke.sciencemag.org/content/vol0/issue2003/images/data/CMP_5533/DC3/Moon1-JW.swf ANIMATION: Wnt signaling - on and off states]
** ‘‘‘[[#GLOSSARY |oncogene]]’’’s such as c-Myc and cyclin D1 involved in cell cycle control <ref><pubmed>22466651</pubmed></ref>
 
** MMP-7 and uPA, associated with metastasis and the invasion of cancer cells <ref><pubmed>22550094</pubmed></ref>
 
  
 
===Tumour Cells===
 
===Tumour Cells===
  
* In a tumour cell, the Wnt siganalling pathway is activated abberantly either:
+
In a tumour cell, the Wnt signalling pathway is activated aberrantly either:
** Innappropriately by an extracellular Wnt signal
+
* Inappropriately by an extracellular Wnt signal
** In the absence of an extracellular Wnt signal
+
* In the absence of an extracellular Wnt signal
*** Usually results from a mutation in one of the subunits that comprise the “destruction complex”, resulting in an inability to degrade cytosolic β-catenin <ref><pubmed>22466651</pubmed></ref>
+
** Usually results from a mutation in one of the subunits that comprise the “destruction complex”, resulting in an inability to degrade cytosolic β-catenin <ref name="PMID22466651"/>
*** Mutant ‘‘‘[[#GLOSSARY |APC]]’’’  proteins characteristic of those associated with cancer, have been shown to upregulate transcription of Wnt target genes due to an inability to regulate levels of cytosolic and nuclear β-catenin <ref name=PMID7708772/>
+
** Mutant [[#Glossary |'''APC''']] proteins characteristic of those associated with cancer, have been shown to upregulate transcription of Wnt target genes due to an inability to regulate levels of cytosolic and nuclear β-catenin <ref name=PMID7708772/>
 
 
  
 
[http://www.youtube.com/watch?v=YuVkRTOYOlQ MOVIE: A detailed explanation of Wnt/β-catenin signalling]
 
[http://www.youtube.com/watch?v=YuVkRTOYOlQ MOVIE: A detailed explanation of Wnt/β-catenin signalling]
  
As described above, the Wnt/β-catenin signalling pathway plays a critical role in development, stem cell regulation and cellular processes such as proliferation and migration. Thus mutations in components of this pathway have been associated with cancers, hereditary disorders, developmental defects and other diseases.
+
==Abnormal Function: Diseases associated with Wnt/β-catenin signalling==
 
+
As described above, the Wnt/β-catenin signalling pathway plays a critical role in development, stem cell regulation and cellular processes such as proliferation and migration. Thus mutations in components of this pathway have been associated with cancers, hereditary disorders, developmental defects and other diseases. In addition, overexpression or underexpression of Wnt responsive genes have also been implicated in cardiovascular disorders such as hypertrophy and myocardial infarction, bone diseases and skin disorders<ref><pubmed>17211410</pubmed></ref><ref><pubmed>16944325</pubmed></ref>. 
  
==Diseases associated with Wnt/β-catenin signalling==
+
[[File:ZFamilial Adenomatous Polyposis.jpg|thumb|right|Figure 6. The colon of a patient with Familial Adenomatous Polyposis (FAP)]]
As described above, the Wnt/β-catenin signalling pathway plays a critical role in development, stem cell regulation and cellular processes such as proliferation and migration. Thus mutations in components of this pathway have been associated with cancers, hereditary disorders, developmental defects and other diseases.
 
  
 +
For a comprehensive list of the range of diseases caused by mutations in Wnt-β-catenin components, please refer to [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861485/table/T1/ Table 1] in [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861485/ Bryan T MacDonald, Keiko Tamai, Xi He Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell: 2009, 17(1);9-26]<ref name=PMID19619488/>
  
===Wnt/B-Catenin Pathway and the Onset of Cancer===
+
===Wnt/β-catenin Pathway and the Onset of Cancer===
The high number of repressor genes involved in the Wnt/β-catenin pathway indicates that it is imperative for this pathway to be tightly regulated. <ref><pubmed>15054482</pubmed></ref>  These repressor genes include APC, Axin 1 and Axin 2. Given the pathways involvements in the regulation of stem cell choice to proliferate or self renew, there is a strong correlation between mutations in these genes and the onset of cancer. The table below describes in further detail some mutations of the Wnt signalling pathway and associated cancers.
 
  
 +
The high number of repressor genes involved in the Wnt/β-catenin pathway indicates that it is imperative for this pathway to be tightly regulated. <ref name="PMID15054482"><pubmed>15054482</pubmed></ref>  These repressor genes include APC, Axin 1 and Axin 2. Given the pathways involvements in the regulation of stem cell choice to proliferate or self renew, there is a strong correlation between mutations in these genes and the onset of cancer. The table below describes in further detail some mutations of the Wnt signalling pathway and associated cancers.
  
 
====Mutations of the Wnt signalling pathway and associated cancers====
 
====Mutations of the Wnt signalling pathway and associated cancers====
 
[[File:ZFamilial Adenomatous Polyposis.jpg|thumb|right|Figure 4. The colon of a Familial Adenomatous Polyposis (FAP) patient]]
 
  
 
{| border="1" cellpadding="5"
 
{| border="1" cellpadding="5"
 
|-style="background:Orange" align="center"
 
|-style="background:Orange" align="center"
! scope="col" width="90" | Gene
+
! scope="col" width="10%" | Gene
! scope="col" width="100" | Normal function
+
! scope="col" width="20%" | Normal function
! scope="col" width="150" | Effects of mutation
+
! scope="col" width="8%" | Mutation
! scope="col" width="100" | Associated cancers <ref name=PMID12781368/>
+
! scope="col" width="35%" | Effects of mutation
 +
! scope="col" width="20%" | Associated cancers <ref name="PMID12781368"/>
 
|-  
 
|-  
 
| style="background: #FFDAB9; color: Black"|'''β-catenin'''
 
| style="background: #FFDAB9; color: Black"|'''β-catenin'''
| style="background: #FFDAB9; color: Black"| Primary Wnt effector. Acts as an oncogene.
+
| style="background: #FFDAB9; color: Black"| Primary Wnt effector. In the nucleus, β-catenin functions as a cofactor for TCF transcription factors which specify a subset of genes, which are responsible for determining cell fate and regulation of proliferation. <ref name="PMID12781368"/>
| style="background: #FFDAB9; color: Black"| In the nucleus, β-catenin functions as a cofactor for TCF transcription factors which specify a subset of genes, such as cyclin D1 and c-MYC, which are responsible for determining cell fate and regulation of proliferation. <ref name=PMID12781368><pubmed>12781368</pubmed></ref> Any mutations that inhibit its destruction motif would cause constitutively active β-catenin signalling, leading to excessive stem cell renewal and proliferation thus predisposing the cells to the formation of tumours. <ref name=PMID15054482><pubmed>15054482</pubmed></ref>
+
| style="background: #FFDAB9; color: Black"| [[#Glossary |'''GOF''']] mutation
 
+
| style="background: #FFDAB9; color: Black"| Any mutations that inhibit its destruction motif would cause constitutively active β-catenin signalling, leading to excessive stem cell renewal and proliferation thus predisposing the cells to the formation of tumours. <ref name="PMID15054482"/>
 
| style="background: #FFDAB9; color: Black"|
 
| style="background: #FFDAB9; color: Black"|
 
*Colorectal cancer
 
*Colorectal cancer
Line 179: Line 348:
 
| style="background: #FFDAB9; color: Black"| '''APC'''
 
| style="background: #FFDAB9; color: Black"| '''APC'''
 
| style="background: #FFDAB9; color: Black"| Facilitates β-catenin degradation; acts as a tumour suppressor
 
| style="background: #FFDAB9; color: Black"| Facilitates β-catenin degradation; acts as a tumour suppressor
| style="background: #FFDAB9; color: Black"| Mutational inactivation of APC inhibits degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. <ref><pubmed>15372092</pubmed></ref> (See β-catenin above).
+
| style="background: #FFDAB9; color: Black"| [[#Glossary |'''LOF''']] mutation
 +
| style="background: #FFDAB9; color: Black"| Mutational inactivation of APC inhibits the degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. <ref name="PMID15372092"><pubmed>15372092</pubmed></ref> (See β-catenin above).
  
  
 
'''Colorectal Cancer (CRC)'''
 
'''Colorectal Cancer (CRC)'''
*APC mutations in intestinal epithelial cells lead constitutive β-catenin/Tcf4 complex activation, causing unrestrained production of crypt stem cells, resulting in cancer. <ref name=PMID22234609/> Once the cancer has spread widely through the body, it is often incurable and management focuses on chemotherapy and improving quality of life.
+
*LOF APC mutations in intestinal epithelial cells lead to constitutive β-catenin/Tcf4 complex activation, causing unrestrained production of crypt stem cells, resulting in cancer. <ref><pubmed>22234609</pubmed></ref> Once the cancer has spread widely through the body, it is often incurable and management focuses on chemotherapy and improving quality of life.
* Activating mutations in the canonical Wnt pathway is responsible for approximately 90% of all colorectal cancer cases. <ref name="PMID19619488"><pubmed>19619488</pubmed></ref> Of these, 85% are caused by loss of function mutations in APC. <ref name=PMID12781368/>  
+
* Activating mutations in the canonical Wnt pathway is responsible for approximately 90% of all colorectal cancer cases. <ref name="PMID19619488"><pubmed>19619488</pubmed></ref> Of these, 85% are caused by loss of function mutations in APC. <ref name="PMID12781368"/>
 
* Colorectal cancer is the fourth most commonly diagnosed cancer in the world.
 
* Colorectal cancer is the fourth most commonly diagnosed cancer in the world.
  
Line 200: Line 370:
 
*Gastric adenoma
 
*Gastric adenoma
 
*Breast fibromatoses  
 
*Breast fibromatoses  
*Familial Adenomatous Polyposis (FAP) [Figure 4]
+
*Familial Adenomatous Polyposis (FAP) [Figure 6]
 
|-
 
|-
 
| style="background: #FFDAB9; color: Black" | '''Axin 1 & Axin 2'''
 
| style="background: #FFDAB9; color: Black" | '''Axin 1 & Axin 2'''
 
| style="background: #FFDAB9; color: Black" | Serve as scaffolding components for the β-catenin degradation complex. Acts as a tumour suppressor.
 
| style="background: #FFDAB9; color: Black" | Serve as scaffolding components for the β-catenin degradation complex. Acts as a tumour suppressor.
| style="background: #FFDAB9; color: Black" | Mutational inactivation of Axin 1 or Axin 2 inhibits degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell.  
+
| style="background: #FFDAB9; color: Black" | [[#Glossary |'''LOF''']] mutation
 +
| style="background: #FFDAB9; color: Black" | Mutational inactivation of Axin 1 or Axin 2 inhibits the degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. (See β-catenin above).  
 
| style="background: #FFDAB9; color: Black" |
 
| style="background: #FFDAB9; color: Black" |
 
*Ovarian carcinoma
 
*Ovarian carcinoma
Line 212: Line 383:
 
|}
 
|}
  
 +
==Current research==
  
For a comprehensive list of human diseases associated with mutations of the Wnt signalling components, please refer to [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861485/table/T1/ Table 1] in the following article: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861485/?tool=pubmed Wnt/β-catenin signaling: components, mechanisms, and diseases]<ref name=PMID19619488><pubmed>19619488</pubmed></ref>
+
===Current Research on Inhibitors to Treat or Prevent Proliferation of Cancer===
  
==Treatment:==
 
 
There is a large focus on finding more effective means of treating and preventing cancer. Current researchers are looking at inhibiting various components of the Wnt/β-catenin pathway to prevent the proliferation of cancer. Such treatments include:
 
There is a large focus on finding more effective means of treating and preventing cancer. Current researchers are looking at inhibiting various components of the Wnt/β-catenin pathway to prevent the proliferation of cancer. Such treatments include:
# Small molecule inhibitors can be used to block the interaction between β-catenin and TCF, thus preventing constitutive transcriptional activities that lead to the proliferation of cancer.  <ref><pubmed>19619488</pubmed></ref>  
+
# Small molecule inhibitors can be used to block the interaction between β-catenin and TCF, thus preventing constitutive transcriptional activities that lead to the proliferation of cancer.  <ref name="PMID19619488"/>
# Non-steroidal anti-inflammatory drugs (NSAIDs) function by interfering with β-catenin/TFC-dependent transcription, and have proven promising for the treatment and prevention of colorectal cancers. <ref><pubmed>19619488</pubmed></ref> Examples of NSAIDs include exisulind, sulindac and aspirin.<ref><pubmed>15372092</pubmed></ref> The success of NSAIDs was measured, indicating a "40-50% reduction in mortality due to CRC in indicidulas taking NSAIDs".<ref><pubmed>19619488</pubmed></ref> Furthermore, studies are being conducted into the use of NSAIDs to inhibit coclooxygenase-2 (COX-2) as an effective method of treatment and prevention of cancers. <ref><pubmed>19619488</pubmed></ref>
+
# Non-steroidal anti-inflammatory drugs (NSAIDs) function by interfering with β-catenin/TFC-dependent transcription, and have proven promising for the treatment and prevention of colorectal cancers. <ref name="PMID19619488"/> Examples of NSAIDs include exisulind, sulindac and aspirin.<ref name="PMID15372092"/> The use of NSAIDs was proven effective with a "40-50% reduction in mortality due to CRC in individuals taking NSAIDs".<ref name="PMID19619488"/> Furthermore, studies are being conducted into the use of NSAIDs to inhibit cyclooxygenase-2 (COX-2) as an effective method of treatment and prevention of cancers. <ref name="PMID19619488"/>
 
# Frizzled-related proteins can be used as natural antagonists to manage the Wnt pathway.
 
# Frizzled-related proteins can be used as natural antagonists to manage the Wnt pathway.
# A “recombinant adenovirus (Ad-CBR) that constitutively expresses the β-catenin binding domain of APC” <ref><pubmed>15578921</pubmed></ref> was developed, enabling APC to maintain its function of β-catenin degradation.
+
# A “recombinant adenovirus (Ad-CBR) that constitutively expresses the β-catenin binding domain of APC” <ref name="PMID15578921"><pubmed>15578921</pubmed></ref> was developed, enabling APC to maintain its function of β-catenin degradation.
# Monoclonal antibodies are being used against Wnt proteins by inducing apoptosis in cancer cells <ref name=PMID15578921/>.
+
# Monoclonal antibodies are being used against Wnt proteins by inducing apoptosis in cancer cells <ref name="PMID15578921"/>.
 +
 
 +
===Other Areas of Current Research===
 +
 
 +
There are a multitude of research groups investigating an array of components making up the Wnt signalling pathway. Four articles most relevant in the context of this wiki page are listed below.
 +
 
 +
'''Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling'''<ref><pubmed>21727895</pubmed></ref>
 +
 
 +
De Lau et al (2011) demonstrated that the stem cell markers Lgr5 and Lgr4 are often co-expressed in Wnt-driven cellular proliferation, where they associate with the [[#Glossary |'''FZ''']]/[[#Glossary |'''LRP''']] Wnt receptor complex. This is of particular importance as the deletion of both the Lgr5 and Lgr4 genes results in decreased proliferation of cells in Wnt-driven compartments (e.g. intestinal crypts in a mouse model), a result similar to the mechanism of the Wnt signalling pathway in its “OFF” state.
 +
 
 +
[http://www.nature.com/nature/journal/v476/n7360/full/nature10337.html Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling]
  
==Key players in Wnt/β-catenin Signalling==
+
[[File:LRP.jpg|350px|thumb|right|Figure 7: Western blot results A. This panel confirms that the absence of protein in knockout cells B. [[#Glossary |'''LRP''']]5 response is weaker despite having two alleles in the absence of [[#Glossary |'''LRP''']]-6, indicating how the majority of signal transduction is mediated through [[#Glossary |'''LRP''']]-6]]
  
{| border="1" cellpadding="5"
+
'''Dissecting Molecular Differences between Wnt Coreceptors [[#Glossary |'''LRP''']]-5 and [[#Glossary |'''LRP''']]-6<ref><pubmed>21887268</pubmed></ref>
|-
+
 
! Protein (Gene)
+
The current understanding of the Wnt signalling pathway is that the [[#Glossary |'''LRP''']]-5/6 co-receptor plays a critical role in the transduction of signals concerning processes such as skeletal remodelling, osteoporosis pathogenesis and cancer formation. MacDonald et al (2011), expand on the canonical understanding of the pathway by differentiating between the [[#Glossary |'''LRP''']]-5 and [[#Glossary |'''LRP''']]-6 co-receptors and the individual processes they are responsible for. By investigating the molecular basis for these differences, it has been demonstrated that the [[#Glossary |'''LRP''']]-6 coreceptor plays a predominant role in embryogenesis and also exhibits a stronger signalling activity in vivo than the [[#Glossary |'''LRP''']]-5 isotype (as depicted in Figure 7).  
! Diagram
+
 
! width="250"|Structure
+
[http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023537 Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6]
! width="450"|Function
+
 
! width="450"|Inhibitors
+
'''Identification of a novel inhibitor of the canonical Wnt pathway'''<ref><pubmed>21576363</pubmed></ref>
|-
+
   
| align="center" | '''Wnt''' (WNT)
+
Because of the vital role Wnt signalling plays in processes such as inflammation, angiogenesis and fibrosis; the identification of a novel inhibitor of the pathway could provide a viable therapeutic intervention for diseases characterised by excessive activation of these processes. One such inhibitor showing promise is pigment epithelium-derived factor ([[#Glossary |'''PEDF''']]), which has been demonstrated to attenuate Wnt signalling induced by conditions such as retinal ischaemia. This is believed to be a result of a physical interaction between [[#Glossary |'''PEDF''']] and the [[#Glossary |'''LRP''']]-6 co-receptor, which blocks initiation of the pathway by preventing activation of the [[#Glossary |'''FZ''']] receptor.
| align="center" width="150px" | [[File:Genomic_structure_and_localization_of_WNT-4.JPG|250px]]
 
| align="center" | Evolutionarily conserved protein across species<ref><pubmed>9407023</pubmed></ref>. Most Wnt proteins figure in the region of 40 kDa, each possessing a characteristic 23 or 24 cysteine residues highly conserved in their spacing. This suggests that the formation of ‘‘‘[[#GLOSSARY |disulfide bonds]]’’’ plays a significant role in determining tertiary protein structure<ref><pubmed>11806834</pubmed></ref>
 
| align="center" | Initiates Wnt signalling when it binds as a ‘‘‘[[#GLOSSARY |ligand]]’’’ to the ‘‘‘[[#GLOSSARY |Fz]]’’’  receptor with ‘‘‘[[#GLOSSARY |LRP]]’’’ <ref><pubmed>9312064</pubmed></ref> and destabilises the β-catenin degradation complex, dephosphorylating β-catenin and subsequently enabling its migration and accumulation in the cell nucleus for gene transcription <ref><pubmed>12781368</pubmed></ref>  
 
|
 
*The FRP family resembles the Wnt-interacting domain of ‘‘‘[[#GLOSSARY |Fz]]’’’  receptors, thus competitvely ‘‘‘[[#GLOSSARY |sequester]]’’’s Wnt from the ‘‘‘[[#GLOSSARY |Fz]]’’’  receptor <ref><pubmed>9118212</pubmed></ref>.
 
*WIF-1 has been shown to competitively antagonise Wnt binding to the ‘‘‘[[#GLOSSARY |Fz]]’’’  receptor <ref><pubmed>10201374</pubmed></ref>
 
*Cerberus is a secreted protein that directly binds to the Wnt protein and inhibits signal transduction <ref><pubmed>10067895</pubmed></ref>
 
*Dkk indirectly inhibits Wnt protein signalling by binding to the co-receptor ‘‘‘[[#GLOSSARY |LRP]]-6’’’, thus making it unable to bind to Wnt for ‘‘‘[[#GLOSSARY |Fz]]’’’  signal transduction <ref><pubmed>11357136</pubmed></ref>
 
* The extracellular sFRP family of proteins possess a consensus ‘‘‘[[#GLOSSARY |CRD]]’’’  sequence on their ‘‘‘[[#GLOSSARY |N-terminus]]’’’, with which they directly bind to Wnt, and prevent its association with ‘‘‘[[#GLOSSARY |Fz]]’’’  receptors, thus antagonising the signal conduction <ref><pubmed>9096311</pubmed></ref>
 
*Experiments suggest that axin indirectly blocks Wnt signalling, in a manner that renders further increases in Wnt levels ineffective <ref><pubmed>9230313</pubmed></ref> 
 
|-
 
| align="center" | ''‘[[#GLOSSARY |Fz]] ''' (FZD)
 
| align="center" width="150px" | [[File:Frizzled.JPG|150px]]
 
| align="center" | ‘‘‘[[#GLOSSARY |Fz]]’’’  houses a ‘‘‘[[#GLOSSARY |CRD]]’’’  on the ‘‘‘[[#GLOSSARY |N-terminus]]’’’, seven transmembrane domains, and a ‘‘‘[[#GLOSSARY |PDZ domain]]’’’ on the ‘‘‘[[#GLOSSARY |C-terminus]]’’’ <ref><pubmed>11806834</pubmed></ref>
 
| align="center" | Binds the Wnt ‘‘‘[[#GLOSSARY |ligand]]’’’ at the extracellular ‘‘‘[[#GLOSSARY |N-terminus]]’’’ for the initiation of the Wnt/β-catenin signalling pathway<ref><pubmed>11806834</pubmed></ref>
 
|
 
|-
 
| align="center" | ''‘[[#GLOSSARY |LRP]]-5/6''' (LRP)
 
| align="center" width="150px" | [[File:LRP6_active_sites.JPG|250px]]
 
| align="center" | A protein that spans multiple domains. The extracellular component is comprised of four EGF-like repeats on the ‘‘‘[[#GLOSSARY |N-terminus]]’’’ <ref><pubmed>11357136</pubmed></ref>
 
| align="center" | Co-receptor to the Wnt ‘‘‘[[#GLOSSARY |ligand]]’’’ in its interaction with the ‘‘‘[[#GLOSSARY |Fz]]’’’  receptor in signal transduction<ref><pubmed>11029008</pubmed></ref>. Causes translocation and association of axin to its intracellular tail, thus destabilising the β-catenin binding activity of axin<ref name=PMID11336703/>
 
|
 
* Dkk antagonises ‘‘‘[[#GLOSSARY |LRP]]-5/6’’’ binding to Wnt through competitive binding<ref><pubmed>11357136</pubmed></ref> and complexes with the transmembrane protein Kremen2 for intracellular removal cell through endocytosis<ref><pubmed>12050670</pubmed></ref>
 
|-
 
| align="center" | ''‘[[#GLOSSARY |Dsh]] ''' (DVL)
 
| align="center" width="150px" | [[File:Dis.JPG|250px]]
 
|
 
| align="center" | Prevents phosphorylatory activity of ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  upon hyperphosphorylation by the Wnt/’‘‘[[#GLOSSARY |LRP]]-5/6’’’ complex binding to the ‘‘‘[[#GLOSSARY |Fz]]’’’  receptor<ref><pubmed>7744250</pubmed></ref>, thus preventing β-catenin ubiquitination and degradation, to promote translocation into the nucleus.
 
|
 
* ‘‘‘[[#GLOSSARY |Nkd]]’’’  blocks feedback signalling, thus inhibiting ‘‘‘[[#GLOSSARY |Dsh]]’’’ <ref><pubmed>11752446</pubmed></ref>
 
* ‘‘‘[[#GLOSSARY |Stbm]]’’’  binds to and jointly immunoprecipitates ‘‘‘[[#GLOSSARY |Dsh]]’’’ <ref><pubmed>12756182</pubmed></ref>
 
* Dapper antagonises ‘‘‘[[#GLOSSARY |Dsh]]’’’  in complex with Axin, ‘‘‘[[#GLOSSARY |GSK-3β]]’’’ , CK-I and β-catenin, leading to degradation of β-catenin and subsequent reduced signalling<ref><pubmed>11970895</pubmed></ref>
 
* ‘‘‘[[#GLOSSARY |PKC]]’’’ , a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits ‘‘‘[[#GLOSSARY |Dsh]]’’’  through phosphorylation, preventing β-catenin nuclear translocation<ref><pubmed>11472835</pubmed></ref>  
 
*Experiments suggest that axin indirectly blocks ‘‘‘[[#GLOSSARY |Dsh]]’’’  function, in a manner that renders further increases in ‘‘‘[[#GLOSSARY |Dsh]]’’’ levels ineffective <ref><pubmed>9230313</pubmed></ref>
 
|-
 
| align="center" | Axin (AXIN)
 
| align="center" width="150px" | [[File:Axin_family_of_proteins.JPG|250px]]
 
|
 
| align="center" | In the absence of Wnt signalling, it constitutes the β-catenin ubiquitination complex along with ‘‘‘[[#GLOSSARY |APC]]’’’  and ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  <ref><pubmed>9312064</pubmed></ref> and its role as a ‘‘‘[[#GLOSSARY |scaffolding protein]]’’’ enhances ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  phosphorylation of β-catenin<ref><pubmed></pubmed>9482734</ref>
 
|
 
*Wnt downregulates axin through increased ‘‘‘[[#GLOSSARY |Dsh]]’’’  expression, hindering axin phosphorylation by GSK-3b, leading to decreased stability and ultimately a shorter half-life<ref><pubmed>10196136</pubmed></ref>
 
|-
 
| align="center" | ''‘[[#GLOSSARY |GSK-3β]] ''' (GSK3β)
 
| align="center" width="150px" | [[File:GSK.JPG|250px]]
 
|
 
| align="center" | Constitutes the β-catenin ubiquitination complex along with axin and ‘‘‘[[#GLOSSARY |APC]]’’’ <ref><pubmed>9312064</pubmed></ref>; its primary role in the Wnt/β-catenin signalling pathway is inhibition of β-catenin nuclear translocation through phosphorylation of three amino acids at the ‘‘‘[[#GLOSSARY |N-terminus]]’’’<ref><pubmed>12027456</pubmed></ref> after priming by ‘‘‘[[#GLOSSARY |CK-I]]’’’ <ref><pubmed>12000790</pubmed></ref>, for subsequent ubiquitination and degradation by the ‘‘‘[[#GLOSSARY |’’’proteasome]]’’’. This activity is enhanced by ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  phosphorylation of axin<ref><pubmed>9482734</pubmed></ref> and ‘‘‘[[#GLOSSARY |APC]]’’’ <ref><pubmed>8638126</pubmed></ref> which appears to promote phosphorylation of β-catenin by ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  in the complex.
 
|
 
* Frat1, which appears to be recruited by ‘‘‘[[#GLOSSARY |Dsh]]’’’  in complex, tightly binds GSK-3b even after complex dissociation and b-catenin degradation<ref><pubmed>10428961</pubmed></ref>
 
* ‘‘‘[[#GLOSSARY |PKC]]’’’  inhibits ‘‘‘[[#GLOSSARY |GSK-3β]]’’’  phosphorylatory activity<ref><pubmed>8887544</pubmed></ref>
 
|-
 
| align="center" | '''Diversin'''
 
| align="center" | [[File:Diversin.JPG|250px]]
 
|
 
| align="center" | Primes b-catenin for degradation by recruiting CK-I to phosphorylate serine 45 on the ‘‘‘[[#GLOSSARY |N-terminus]]’’’ before subsequent phosphorylation of threonine 41, serine 37 and serine 33 by GSK-b and degradation by E3 ubiquitin ligase β-TrCP<ref><pubmed>12000790</pubmed></ref>
 
|
 
|-
 
| align="center" | ''‘[[#GLOSSARY |APC]] ''' (APC)
 
| align="center" width="150px" | [[File:APC.JPG|150px]]
 
| align="center" | A large 312 kDa protein
 
| align="center" | Possesses a numerous and varied set of roles ranging from cell migration and adhesion, cell cycle regulation and chromosome stability<ref><pubmed>11978510</pubmed></ref>. In the Wnt/β-catenin signalling pathway, ‘‘‘[[#GLOSSARY |APC]]’’’  constitutes the β-catenin ubiquitination complex along with axin and ‘‘‘[[#GLOSSARY |GSK-3β]]’’’ <ref><pubmed>9312064</pubmed></ref>. It binds to axin via ‘‘‘[[#GLOSSARY |SAMP]]’’’  elements<ref name=PMID9554852/>, and to β-catenin via three 15-amino acid repeats and seven 20-amino acid repeats<ref><pubmed>10526234</pubmed></ref>
 
|
 
|-
 
| align="center" | '''β-catenin''' (CTNNB1)
 
| align="center" width="150px" | [[File:Murine_bcat.jpg|250px]]
 
| align="center" | The ‘‘‘[[#GLOSSARY |N-terminus]]’’’ accommodates a critical sequence of thirteen armadillo repeats that competitively bind E-cadherin, ‘‘‘[[#GLOSSARY |LEF]]-1’’’ and ‘‘‘[[#GLOSSARY |APC]]’’’ <ref><pubmed>10966653</pubmed></ref>. The ‘‘‘[[#GLOSSARY |C-terminus]]’’’  houses a glycine-rich transactivation domain<ref><pubmed>9118222</pubmed></ref>
 
| align="center" | Involved in mediating both ‘‘‘[[#GLOSSARY |morphogenesis]]’’’ and maintenance of tissue integrity in the endothelium, bound to a-catenin that subsequently binds to the actin cytoskeleton. Gene expression is mediated in conjunction with ‘‘‘[[#GLOSSARY |TCF]] /[[#GLOSSARY |LEF]]’’’, upon translocation from the cytosol into the nucleus<ref><pubmed>10966653</pubmed></ref>
 
|
 
* The axin/’‘‘[[#GLOSSARY |APC]]’’’ /GSK-β complex phosphorylates b-catenin and marks it for ubiquitination and degradation by the ‘‘‘[[#GLOSSARY |’’’proteasome]]’’’<ref><pubmed>12781368</pubmed></ref>
 
|-
 
| align="center" | '''[[#GLOSSARY |TCF]] /[[#GLOSSARY |LEF]] ''' (TCF7/LEF)
 
| align="center" width="150px" | [[File:Protein_structure_LEF1_TCF4_TCF3.JPG|250px]]
 
| align="center" | The ‘‘‘[[#GLOSSARY |N-terminus]]’’’ constitutes the β-catenin interaction domain; ‘‘‘[[#GLOSSARY |TCF]] /[[#GLOSSARY |LEF]]’’’ also possesses a ‘‘‘[[#GLOSSARY |HMG]]’’’  box DNA-binding domain<ref><pubmed>9118222</pubmed></ref>
 
| align="center" | Mediates DNA binding when in complex with β-catenin; the ‘‘‘[[#GLOSSARY |N-terminus]]’’’ of ‘‘‘[[#GLOSSARY |TCF]] /[[#GLOSSARY |LEF]]’’’  associates with the β-catenin ‘‘‘[[#GLOSSARY |C-terminus]]’’’ <ref><pubmed>9118222</pubmed></ref>
 
|
 
*’‘‘[[#GLOSSARY |CAMKII]]’’’ , a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits ‘‘‘[[#GLOSSARY |LEF]]’’’  downstream of β-catenin, acting at the transcription factor complex level<ref><pubmed>11472835</pubmed></ref>
 
|}
 
  
==Embryonic development==
+
[http://mcb.asm.org/content/31/14/3038.long Identification of a Novel Inhibitor of the Canonical Wnt Pathway]
  
[[File:Wnt.JPG|200px|thumb|right|Figure 5. Neural crest stem cells that were cultured with bone morphogenic protein (BMP) and Wnt were shown to maintain stem cell markers (indicated in red and green)]]’’’
+
'''Inhibition of GSK3 by Wnt signalling - two contrasting models'''<ref><pubmed>22083140</pubmed></ref>
  
The Wnt/β-catenin signaling pathway has been implicated as an important pathway in human fetal development. Through immunohistochemical staining, Eberhart and Argani (2001) localised nuclear beta catenin in fetal lung, placenta, kidney, cartilage, capillaries, adrenal glands and skin. This indicates that Wnt signaling regulates the development of specific set of organs and tissues.<ref><pubmed>11441336</pubmed></ref> For example, Wnt genes such as Wnt4 regulate the conversion of mesenchyme to epithelial cells in kidney ‘‘‘[[#GLOSSARY |morphogenesis]]’’’.
+
We have discussed the role of GSK-3β in the phosphorylation of β-catenin and subsequent ubiquitylation and proteosomal degradation of the protein (“off” state), although the mechanism by which Wnt activation inhibits these events (“on state”) is unclear. This is an important step because by blocking the phosphorylation of β-catenin, the protein is able to accumulate in the cytoplasm and carry out its biological function by promoting the transcription of Wnt target genes. Metcalfe and Bienz (2011) investigated two models proposing contrasting mechanisms by which GSK-3β is inhibited by Wnt activation. The first model proposed that Wnt induces the phosphorylation of [[#Glossary |'''LRP''']]-6, which consequently inhibits the catalytic activity of GSK-3β, thereby preventing phosphorylation of β-catenin. The second model suggested that Wnt signalling induces the uptake of GSK-3β in vesicles called multivesicular bodies ([[#Glossary |'''MVBs''']]), and therefore prevents any interaction between the enzyme and its substrate, β-catenin. The study also tested whether either of the models have any inclination to predominate in an acute vs. chronic setting of Wnt signalling.
  
In addition, Wnt/β-catenin signaling is also involved in maintaining the ‘‘‘[[#GLOSSARY |pluripotency]]’’’ of human embryonic stem cells (hESCs). Wnt3a promotes the reprogramming of somatic cells to ‘‘‘[[#GLOSSARY |pluripotency]]’’’ in conjunction with the classical transcription factors, Oct4, Sox2 and Nanog.<ref><pubmed>18682236</pubmed></ref> For example, Oct4 has the effect of repressing Wnt/β-catenin signaling in self renewing hESCs and is depressed during hESC ‘‘‘[[#GLOSSARY |differentiation]]’’’  .<ref><pubmed>22392999</pubmed></ref> Hence, this suggests that Wnt/β-catenin signaling is involved in ‘‘‘[[#GLOSSARY |differentiation]]’’’  rather than ‘‘‘[[#GLOSSARY |self renewal]]’’’.
+
[http://jcs.biologists.org/content/124/21/3537.long Inhibition of GSK3 by Wnt signalling – two contrasting models]
  
 
==Future directions==
 
==Future directions==
  
* What is the mode of translocation of β-catenin into the nucleus upon dissociating with axin?<ref name=PMID11336703/>
+
Although the Wnt/β-catenin signalling pathway has been well-established, there are many aspects that add complexity to this signal transduction pathway. The journal articles below are examples of areas of Wnt signalling that could potentially be investigated in the future.
* Elucidate the mechanism for the hyperphosphorylation of ‘‘‘[[#GLOSSARY |Dsh]]’’’  by Wnt/’‘‘[[#GLOSSARY |Fz]] /LRP-5/6 binding concurrent to, but mutually exclusive from, axin destabilisation<ref><pubmed>7744250</pubmed></ref>
+
 
* The biochemical events connecting the components of the canonical Wnt pathway
+
'''The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review.''' <ref name="PMID22399606"><pubmed>22399606</pubmed></ref>
* Production of purified Wnt proteins to assist with research
+
 
* Production of effective Wnt antibodies
+
This review article highlights the importance of the Wnt/β-catenin pathway to the pathogenesis of oral carcinogenesis. What is still poorly understood in the quest for a cure is the role, if any, of Wnt/β-catenin signalling in apoptosis, a crucial mode of combatting abnormal cell proliferation.
* Structure of the Wnt1 protein
+
Although much has been established in the mechanism of action of the canonical pathway, this topic of research is also relevant to developing treatments for many other diseases that are impacted by abnormalities in the apoptotic function of cells, and hence the continued interest in such research.
* Complete understanding of the routing and the coincident posttranslational modifications of Wnt proteins in the secreting cell
+
 
* The rules that dictate the movement of Wnt proteins between cells
+
[http://ar.iiarjournals.org/content/32/3/873.long The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review]
* The biochemistry of the activities of the destruction complex
+
 
 +
'''Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation.''' <ref name="PMID22434869"><pubmed>22434869 </pubmed></ref>
 +
 
 +
Chen et al. have demonstrated the necessity of secreted Wnt ligands in not only fibroblast precursors, but also for the proliferation of fibroblasts, leading to thickening of the dermis, as well as hair follicles. However, the mechanism of the involvement of the secreted Wnt ligands in dermal fbroblast proliferation is yet to be defined, still resting on the determination of which broadly expressed Wnt ligands are required for dermal β-catenin activity, as well as what role (if any) dermal cell density plays in hair follicle formation. Elucidating such interactions pose implications for addressing diseases such as congenital human focal dermal hypoplasia and skin fibrosis.
  
Taken from ''Wnt signaling: a common theme in animal development''<ref><pubmed>9407023</pubmed></ref> - the research outlined will be explored in the current literature
+
[http://dev.biologists.org/content/139/8/1522.long Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation ]
* How do the ‘‘‘[[#GLOSSARY |Fz]]’’’  receptors work?
 
* What is ‘‘‘[[#GLOSSARY |Dsh]]’’’  doing to transduce the signal?
 
* What is the relationship between ‘‘‘[[#GLOSSARY |APC]]’’’  and Wnt signaling?
 
* How does Arm/β-catenin get into the nucleus?
 
  
 
==Glossary==
 
==Glossary==
Line 341: Line 445:
 
===List of Abbreviations Used===
 
===List of Abbreviations Used===
 
* '''APC:''' adenomatous polyposis coli
 
* '''APC:''' adenomatous polyposis coli
* ''’CAMKII:''' Ca2+/calmodulin-dependent protein kinase II
+
* '''CAMKII:''' Ca2+/calmodulin-dependent protein kinase II
 
* '''CK-I:''' casein kinase I
 
* '''CK-I:''' casein kinase I
 
* '''CRD:''' cysteine rich domain
 
* '''CRD:''' cysteine rich domain
 +
* '''CRM1:''' exportin-1 protein
 +
* '''DIX:''' dishevelled and axin domain
 
* '''Dsh:''' Dishevelled
 
* '''Dsh:''' Dishevelled
 
* '''Fz:''' Frizzled
 
* '''Fz:''' Frizzled
 +
* '''GOF:''' gain of function mutation
 
* '''GSK-3β:''' glycogen synthase kinase-3β
 
* '''GSK-3β:''' glycogen synthase kinase-3β
 
* '''HMG:''' high mobility group
 
* '''HMG:''' high mobility group
 
* '''LEF:''' lymphoid enhancer-binding factor
 
* '''LEF:''' lymphoid enhancer-binding factor
 +
* '''LMB:''' leptomycin B
 +
* '''LOF:''' loss of function mutation
 
* '''LRP:''' lipoprotein receptor–related protein
 
* '''LRP:''' lipoprotein receptor–related protein
 +
* '''MVB:''' multi-vesicular body
 +
* '''NES:''' leucine-rich nuclear export signal protein
 
* '''Nkd:''' naked cuticle
 
* '''Nkd:''' naked cuticle
 +
* '''NSAIDs:''' non-steroidal anti-inflammatory drugs
 +
* '''PEDF:''' pigment epithelium-derived factor
 
* '''PKC:''' protein kinase C
 
* '''PKC:''' protein kinase C
 
* '''SAMP:''' Ser-Ala-Met-Pro repeated amino acid segment
 
* '''SAMP:''' Ser-Ala-Met-Pro repeated amino acid segment
Line 357: Line 470:
  
 
===List of Terminology===
 
===List of Terminology===
* agenesis:
+
* '''Agenesis:''' the inability to form an organ during embryogenesis due to the lack of primordial tissues
* agonist:
+
* '''Agonist:''' a molecule which binds to a receptor to produce a physiological response
* antagonist:
+
* '''Antagonist:''' a molecule which inhibits the physiological function of another substance
* apoptosis:
+
* '''Apoptosis:''' programmed cell death
 
* '''C-terminus:''' the end of the polypeptide chain which features a free carboxyl group (-COOH)  
 
* '''C-terminus:''' the end of the polypeptide chain which features a free carboxyl group (-COOH)  
* '''canonical:''' standard and well accepted
+
* '''Canonical:''' standard and well accepted
* destruction motif:
+
* '''Caveolin:''' integral membrane proteins involved in receptor mediated endocytosis
* '''differentiation:''' the process by which cells become mature and specialised in structure and function
+
* '''Destruction motif:''' short sequences which provide stability of other proteins when deleted or mutated
* disulfide bonds:
+
* '''Differentiation:''' the process by which cells become mature and specialised in structure and function
* gain of function mutation:
+
* '''Disulfide bonds:''' a covalent bond between sulfur atoms
* '''glycolipoprotein:''' a protein with attached lipid and carbohydrate groups
+
* '''Gain of function mutation:''' mutation produces a protein which has an enhanced or abnormal function
* '''homeotic gene:''' genes involved in embryonic development, specifically controlled the anterior-posterior axis  
+
* '''Glycolipoprotein:''' a protein with attached lipid and carbohydrate groups
* histone deacetylation:
+
* '''Histone deacetylation:''' the process by which histone deacetylase removes acetyl groups on the histones to increase affinity and condense DNA, thus preventing transcription
* homolog:
+
* '''Homeotic gene:''' genes involved in embryonic development, specifically controlled the anterior-posterior axis  
* immunohistochemistry:
+
* '''Homolog:''' gene which is related to another gene by common descent
* immunoprecipitation:
+
* '''Immunohistochemistry:''' detecting antigens on a tissue using labelled antibodies
* lethal mutation:
+
* '''Immunoprecipitation:''' the process of isolating a protein antigen using an antibody that binds to it to form an insoluble complex
* ligand:
+
* '''Lethal mutation:''' a mutation which can result in the death of the organism
* loss of function mutation:
+
* '''Ligand:''' a molecule which binds to another entity
* monoclonal antibody:
+
* '''Loss of function mutation:''' mutation produces a protein which has decreased or no function
* morphogenesis:
+
* '''Metastasis:''' distant non adjacent spread of a tumour
 +
* '''Mnemonic:''' a tool which assists memory
 +
* '''Monoclonal antibody:''' an antibody engineered from a single clone of cells
 +
* '''Morphogenesis:''' the differentiation and growth of tissues and organs during embryo development
 
* '''N-terminus:''' the start of the polypeptide chain which features a free amine group (-NH2)   
 
* '''N-terminus:''' the start of the polypeptide chain which features a free amine group (-NH2)   
* '''oncogene:''' genes which transform normal cells into cancerous cells
+
* '''Oncogene:''' genes which transform normal cells into cancerous cells
* '''pluripotency:''' the ability of stem cells to differentiate into ectoderm, mesoderm and endoderm
 
 
* '''PDZ domain:''' a common structural domain of 80-90 amino acids of signalling proteins, whose name is derived from the first three letters of the first three proteins to be discovered to share the domain: post synaptic density protein, Drosophila disc large tumor suppressor, zonula occludens-1 protein
 
* '''PDZ domain:''' a common structural domain of 80-90 amino acids of signalling proteins, whose name is derived from the first three letters of the first three proteins to be discovered to share the domain: post synaptic density protein, Drosophila disc large tumor suppressor, zonula occludens-1 protein
* '''proteasome:''' a large intracellular particle which degrades proteins
+
* '''Pluripotency:''' the ability of stem cells to differentiate into ectoderm, mesoderm and endoderm
* repressor:
+
* '''Proteasome:''' a large intracellular particle which degrades proteins
* '''self renewal:''' the capability to undergo numerous cell divisions and maintain undifferentiation
+
* '''Repressor:''' a protein which binds to the operator and prevents transcription
* sequester:  
+
* '''Scaffolding protein:''' proteins which regulate signal transduction by organising and assembling signalling complexes
* scaffolding protein:
+
* '''Self renewal:''' the capability to undergo numerous cell divisions and maintain undifferentiation
* tumour suppressor gene:
+
* '''Sequester:''' to isolate or separate
* '''ubiquitylation:''' the process of adding ubiquitin
+
* '''siRNA:''' small interfering RNA which is involved in RNA interference
 +
* '''Synergism:''' the joint action of two substances which increases their effectiveness
 +
* '''Tumour suppressor gene:''' produces proteins which control cell growth to prevent uncontrolled cell proliferation
 +
* '''Ubiquitylation:''' the process of adding ubiquitin
  
 
==External links==
 
==External links==

Latest revision as of 03:34, 28 May 2012


2012 Projects: Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | Group 7 | Group 8 | Group 9
Figure 1. 30 Years of Wnt Signalling Conference


Wnt/β-catenin Signalling Pathway

2012 marks the 30th anniversary of the identification of Wnt-1, the first component of the Wnt signaling pathway to be discovered. Since this breakthrough, researchers from around the globe have extensively studied and pieced together the multiple components that form the Wnt signaling pathway as it is known and accepted today.

Introduction

The classical pathway of Wnt signalling that is best understood in current research is the Wnt/β-catenin signalling pathway. This signal transduction pathway is evolutionarily conserved and features heavily in development, regeneration, stem cell regulation and cellular processes such as proliferation and migration[1].

The term 'Wnt' was coined to reflect the homolog genes: Wingless in Drosophila and Int-1 in mammals. Wnt proteins encompass a network of secreted glycolipoproteins[1], forming the basis of this highly conserved pathway. The various elements, agonists and antagonists of this pathway will be discussed, with key emphasis on the structure and function.

Furthermore, mutations in components of this pathway have been associated with cancers, developmental defects and other diseases which will be discussed in further detail.

It is important to note that the Wnt/β-catenin signalling pathway is becoming increasingly complex with the addition of new molecules being discovered in recent years. Areas of current research and future directions will also be outlined.

History

Year Significant Discovery
1973
  • A mutant of Drosophila melanogaster which had no wings was characterised as Wingless (Wg) [2]
1982
  • Roel Nusse and Harold Varmus found that mouse mammary tumour virus (MMTV) stimulated tumour formation when the Int1 (integration 1) gene was activated.[3]
1987
  • Rijsewijk et al identifies the mammalian homolog of the Drosophila Wingless gene as Int1.[4]
1989
  • Screening of zygotic lethal mutations in Drosophila identified new Wnt signalling molecules e.g. Dishevelled and Shaggy.[5]
1990
  • Riggleman et al reports on how the accumulation of Armadillo (mammalian homolog is beta-catenin) in Drosophila is posttranscriptionally controlled by the Wingless gene.[6]
  • Through nucleotide sequence analysis and peptide mapping, APC was found to associated with β-catenin[7][8]
1991
  • The nomenclature of Wingless and Int-1 was combined to form the mnemonic, Wnt[9].
  • Molecular cloning of β-catenin[10], LEF (lymphoid enhancer factor)[6] and TCF (T-cell factor)[11] transcription factors was conducted.
1992
  • Wingless signaling was discovered to be regulated by zeste-white 3 (also called Shaggy), which is the Drosophila homolog of mammalian Glycogen Synthase Kinase-3 (GSK -3).[12]
1994
  • Mutations in Dishevelled affected phenotype and gene expression, indicating its crucial role in the Wnt signalling pathway[13]
1995
  • APC is involved in the degradation of β-catenin and hence regulates its cytoplasmic levels[14]
1996
  • The interaction of β-catenin with the transcription factors LEF and TCF was discovered[15]
  • Bhanot et al identifies Frizzled as a receptor for Wnt ligands[16]
  • A transmembrane protein identified as Porcupine was found to be involved in the processing of Wnt ligands[17]
  • β-catenin levels were reported to be three times higher in tumour tissues than in normal specimens, indicating the link between β-catenin accumulation and colorectal cancers[18]
1997
  • Huber et al investigates the three dimensional structure of β-catenin[19].
  • Phosphorylation of β-catenin by GSK3β (in the absence of Wnt) signals degradation via ubiquitin/proteasome[20].
  • The gene expression of the homeotic gene Ubx is discovered to be controlled by Wnt signalling, thus implicating Ubx as the first Wnt target gene[21]
1998
  • Axin-1 and Axin-2 were found to be important components of the 'destruction complex' (GSK 3β and APC) and promoted the phosphorylation of β–catenin[22][23]
1999
  • Peters et al identifies the function of Casein kinase 1 (CK1) in increasing the phosphorylation of LRP, boosting its ability to recruit Axin[24].
  • Protein phosphatase (PP2A) is involved in the regulation of GSK3β-dependent phosphorylation of β–catenin[25][26]
2000
  • Graham et al determines the 3D crystal structure of the β-catenin–TCF complex[27].
  • Low-density lipoprotein receptor-related proteins (LRP) such as LRP-5 and LRP-6 interact with Wnt proteins and function as coreceptors of the Fz receptor[28]
2001
  • Wnt protein interacts with LRP-5 and enhances the binding of axin to the intracellular domain of LRP-5[29]
2003
  • An alternate Wnt receptor, besides Fz, was recognised as Derailed in Drosophila (RYK in mammals)[30].
  • Xing et al determines the crystal structure of the β-catenin/Axin complex and investigates the structural interactions between them[31]
2006
  • Caveolin is involved in internalising the LRP-6 receptor and inhibits the binding of β-catenin to Axin[32]
2007
  • Dishevelled polymerises when recruited to the plasma membrane, allowing it to act as a scaffold for other interactions[33]
2008
  • Using an siRNA screen, Major et al identified AGGF1 as a chromatin associated protein that involved in regulating β-catenin mediated transcription[34]
2010
  • A mediator of Hippo signalling known as TAZ inhibits Wnt signalling by binding to Dishevelled[35]

Key players in Wnt/β-catenin signalling

This table provides an introduction to the various proteins involved in what would be a complex interaction in the Wnt/β-catenin signalling pathway. It is aimed to simplify the following mechanisms of action by elucidating the characteristics of each protein. For each protein listed, the gene from which it is derived is given in brackets, followed by a column providing an illustration to help the reader better picture the respective protein. The general function and antagonists are also outlined for reference.

Protein (Gene) Diagram Structure Function Inhibitors
Wnt (WNT) 250px Evolutionarily conserved protein across species.[36] Most Wnt proteins figure in the region of 40 kDa, each possessing a characteristic 23 or 24 cysteine residues highly conserved in their spacing. This suggests that the formation of disulfide bonds plays a significant role in determining tertiary protein structure[37] Initiates Wnt signalling when it binds as a ligand to the Fz receptor with LRP[38] and destabilises the β-catenin degradation complex, dephosphorylating β-catenin and subsequently enabling its migration and accumulation in the cell nucleus for gene transcription [39]
  • The FRP family resembles the Wnt-interacting domain of Fz receptors, thus competitively sequesters Wnt from the Fz receptor[40].
  • WIF-1 has been shown to competitively antagonise Wnt binding to the Fz receptor [41]
  • Cerberus is a secreted protein that directly binds to the Wnt protein and inhibits signal transduction [42]
  • Dkk indirectly inhibits Wnt protein signalling by binding to the co-receptor LRP-6, thus making it unable to bind to Wnt for Fz signal transduction [43]
  • The extracellular sFRP family of proteins possess a consensus CRD sequence on their N-terminus, with which they directly bind to Wnt, and prevent its association with Fz receptors, thus antagonising the signal conduction [44]
  • Experiments suggest that axin indirectly blocks Wnt signalling, in a manner that renders further increases in Wnt levels ineffective [45]
Fz(FZD) 150px Fz houses a CRD on the N-terminus, seven transmembrane domains, and a PDZ domain on the C-terminus[37] Binds the Wnt ligand at the extracellular N-terminus for the initiation of the Wnt/β-catenin signalling pathway[37]
  • For inhibitors of the Fz receptor, refer to "Inhibitors" under Wnt
LRP-5/6 (LRP) 250px A protein that spans multiple domains. The extracellular component is comprised of four EGF-like repeats on the N-terminus[43] Co-receptor to the Wnt ligand in its interaction with the Fz receptor in signal transduction[46]. Causes translocation and association of axin to its intracellular tail, thus destabilising the β-catenin binding activity of axin[29]
  • Dkk antagonises LRP-5/6 binding to Wnt through competitive binding[43] and complexes with the transmembrane protein Kremen2 for intracellular removal cell through endocytosis[47]
Dsh (DVL) 250px A phosphoprotein [48] approximately 670 amino acids long [49]. Possesses a DIX domain, which is thought to facilitate interaction with Axin [50]. Prevents phosphorylatory activity of GSK-3β upon hyperphosphorylation by the Wnt/LRP-5/6 complex binding to the Fz receptor[51], thus preventing β-catenin ubiquitination and degradation, to promote translocation into the nucleus.
  • Nkd blocks feedback signalling, thus inhibiting Dsh[52]
  • Stbm binds to and jointly immunoprecipitates Dsh[53]
  • Dapper antagonises Dsh in complex with Axin, GSK-3β, CK-I and β-catenin, leading to degradation of β-catenin and subsequent reduced signalling[54]
  • PKC, a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits Dsh through phosphorylation, preventing β-catenin nuclear translocation[55]
  • Experiments suggest that axin indirectly blocks Dsh function, in a manner that renders further increases in Dsh levels ineffective [45]
Axin (AXIN) 250px A 95.635 kDa protein[56]. Possesses a DIX domain, which is thought to facilitate interaction with Dsh [57]. In the absence of Wnt signalling, it constitutes the β-catenin ubiquitination complex along with APC and GSK-3β[38] and its role as a scaffolding protein enhances GSK-3β phosphorylation of β-catenin[58]
  • the antibiotic LMB prevents nuclear shuttling by blocking the NES- CRM1 interaction
  • Wnt downregulates axin through increased Dsh expression, hindering axin phosphorylation by GSK-3β, leading to decreased stability and ultimately a shorter half-life[59]
GSK-3β(GSK3β) 250px 46 kDa kinase [60]. Possesses a surface channel on the hydrophobic C-terminal helical domain that binds a 19 amino acid residue on Axin [61]. Constitutes the β-catenin ubiquitination complex along with axin and APC[38]; its primary role in the Wnt/β-catenin signalling pathway is inhibition of β-catenin nuclear translocation through phosphorylation of three amino acids at the N-terminus[62] after priming by CK-I[63], for subsequent ubiquitination and degradation by the proteasome. This activity is enhanced by GSK-3β phosphorylation of axin[58] and APC[64] which appears to promote phosphorylation of β-catenin by GSK-3β in the complex.
  • Frat1, which appears to be recruited by Dsh in complex, tightly binds GSK-3β even after complex dissociation and β-catenin degradation[65]
  • PKC inhibits GSK-3β phosphorylatory activity[66]
Diversin (ANKRD6) Diversin.JPG 776 amino acid with multiple ankyrin repeat domains [67]. Primes β-catenin for degradation by recruiting CK-I to phosphorylate serine 45 on the N-terminus before subsequent phosphorylation of threonine 41, serine 37 and serine 33 by GSK-3β and degradation by E3 ubiquitin ligase β-TrCP[63] There are no known inhibitors of Diversin in the published literature.
APC (APC) 150px A large 312 kDa protein [68]. Possesses a 25 amino acid SAMP repeat that is sufficient for full Axin binding [69] Possesses a numerous and varied set of roles ranging from cell migration and adhesion, cell cycle regulation and chromosome stability[70]. In the Wnt/β-catenin signalling pathway, APC constitutes the β-catenin ubiquitination complex along with axin and GSK-3β[38]. It binds to axin via SAMP elements[22], and to β-catenin via three 15-amino acid repeats and seven 20-amino acid repeats[71]
  • APC is itself an inhibitor of the β-catenin. For inhibitors of APC in the Wnt/β-catenin signalling pathway, refer to "Inhibitors" under Axin
β-catenin (CTNNB1) Murine bcat.jpg The N-terminus accommodates a critical sequence of thirteen armadillo repeats that competitively bind E-cadherin, LEF-1 and APC[72]. The C-terminus houses a glycine-rich transactivation domain[73] Involved in mediating both morphogenesis and maintenance of tissue integrity in the endothelium, bound to a-catenin that subsequently binds to the actin cytoskeleton. Gene expression is mediated in conjunction with TCF /LEF, upon translocation from the cytosol into the nucleus[72] The axin/APC/GSK-β complex phosphorylates β-catenin and marks it for ubiquitination and degradation by the proteasome[39]
TCF /LEF (TCF7/LEF) Protein structure LEF1 TCF4 TCF3.JPG The N-terminus constitutes the β-catenin interaction domain; TCF /LEF also possesses a HMG box DNA-binding domain[73] Mediates DNA binding when in complex with β-catenin; the N-terminus of TCF /LEF associates with the β-catenin C-terminus[73]
  • CAMKII, a serine/threonine-specific protein kinase product of the non-canonical Wnt/Ca2+ pathway, inhibits LEF downstream of β-catenin, acting at the transcription factor complex level[55]

Normal function: Roles of Wnt/β-catenin signalling

Embryonic development

Figure 2. Stem cell markers (red and green) in neural crest stem cells cultured with Wnt

The Wnt/β-catenin signaling pathway has been implicated as an important pathway in human fetal development. Through immunohistochemical staining, Eberhart and Argani (2001) localised nuclear beta catenin in fetal lung, placenta, kidney, cartilage, capillaries, adrenal glands and skin. This indicates that Wnt signaling regulates the development of specific set of organs and tissues.[74] For example, Wnt genes such as Wnt4 regulate the conversion of mesenchyme to epithelial cells in kidney morphogenesis.

In addition, Wnt/β-catenin signaling is also involved in maintaining the pluripotency of human embryonic stem cells (hESCs). Wnt3a promotes the reprogramming of somatic cells to pluripotency in conjunction with the classical transcription factors, Oct4, Sox2 and Nanog.[75] For example, Oct4 has the effect of repressing Wnt/β-catenin signaling in self renewing hESCs and is depressed during hESC differentiation[76]. Hence, this suggests that Wnt/β-catenin signaling is involved in differentiation rather than self renewal.

Adult tissue self renewal

Figure 3. Crypt villous junction, indicating the location of the progenitor compartment

Wnt/β-catenin signalling features in a great variety of processes during embryogenesis however the interesting concept to note about Wnt/β-catenin signalling is that it is heavily involved in adult tissue self renewal as well [1]. For example, in the gut, Wnt signaling is essential for the establishment of the progenitor compartment in an intestinal crypt [1]. This is further supported by Kuhnert et al (2004) who noted that the inhibition of Wnt signalling results in the loss of crypts[77]. This means Wnt provides the mitotic stimulus for the progenitor cells in the crypts to proliferate.

Wnt/β-catenin signalling is also involved in the self renewal of bone tissue where several mouse models established the importance of Wnt signaling in bone homeostasis[1]. For instance, Babij et al (2003) observed how mice with gain of function mutations in LRP-5 (in osteoblasts) results in increased bone density and osteoclast activation[78]. In contrast, Kato et al (2002) noted how a loss of function in LRP-5 lead to decreased bone mass and faulty osteoblast maturation[79]. Hence, Wnt signalling plays an essential role in maintaining the maturation and proliferation of osteoblasts.

Other tissues involved in self renewal via Wnt signaling include hair follicles and the haematopoietic system[1].

Migration

Muller et al (2002) investigated how Wnt/beta catenin signalling is involved in the stimulation of epithelial cell motility[80]. They discovered that when β-catenin was activated, it had the ability to induce epithelial migration in cell culture. Furthermore, the addition of growth factors enhanced the transcriptional activity of β-catenin and induced more migration than beta catenin alone[81]. This indicates evidence of synergism between Wnt signalling pathways and growth factors, which is particularly relevant in cancers. As a result, the cooperation between Wnt signaling and growth factors are likely stimulators of tumour progression and possibly the capacity to migrate and metastasise[81].

Figure 4. Comparison of canonical and non-canonical Wnt signaling

Comparison with non-canonical Wnt signalling

Wnt/β-catenin signalling is commonly referred to as the canonical Wnt signalling pathway, and its function is primarily centered around the differentiation and proliferation of cells in adults and embryos. In contrast, the non-canonical Wnt signalling pathways include the Planar Cell Polarity (PCP) pathway and Wnt/Calcium pathways, and are involved in regulating cell polarity, neural migration and myogenesis[82]. Despite their differences in intracellular effectors and function, these pathways have been known to cross talk with each other, for example during axis formation in Xenopus[83]

Normal function: Mechanism of action

β-catenin commonly exists as a subunit making up the cadherin protein complex, where it links E-cadherin to α-catenin[84]. Cadherin proteins play an integral role in the formation of adhesion junctions between cells [84], and β-catenin in particular acts to help anchor the actin cytoskeleton within the cell[84]. The β-catenin gene can be said to function as an oncogene given that the promotion of transcription of Wnt target genes by β-catenin has been shown to be involved in the development of an array of cancers including basal cell carcinoma, colorectal cancer and breast cancer.[85][86][87]

In the absence of Wnt (“off state”)

Figure 4. Wnt signalling in the "off" state


1. No extracellular "Wnt signal"


2. β-catenin targeted for proteosomal degradation by its incorporation into a “destruction complex” comprising:


3. APC and axin assemble into a structural scaffold, allowing the phosphorylation of the N-terminal of β-catenin by the coordinated action of CK1 and GSK-3β[89]


4. β-catenin is recognised by E3 ligase β-Trcp, ubiquinated and subsequently degraded by the 26S proteosome [90][38]


5. Level of β-catenin in the cytosol is low, and therefore does not reach the nucleus at a level sufficient enough to affect transcription


6. No transcription of Wnt target genes


In the presence of Wnt (“on state”)

Figure 5. Wnt signalling in the "on" state


1. Extracellular “Wnt signal” binds to a cell surface G-protein coupled receptor of the “Frizzled” (FZ) family


2. Low-density lipoprotein receptor-related protein (LRP) family functions as a transmembrane co-receptor for FZ

  • Recruitment of axin to the membrane where it is degraded upon initiation of the Wnt signalling cascade
  • Dissociation of β-catenin into the cytoplasm without degradation by the “destruction complex" [93][38]


3. Activation (phosphorylation and poly-ubiquination) of proteins of the “Dishevelled” (Dsh) family

  • Implicated in the inactivation of the “destruction complex” by the recruitment of axin and GSK-3β away from the complex [94]


4. With the complex now interrupted, β-catenin resists ubiquination and reaches the nucleus in increased levels where it functions as a transcriptional enhancer alongside TCF[88]


5. β-catenin directly competes with Groucho/TLEs for TCF binding [95]

  • TCF promotes binding of RNA polymerase to DNA template strand


6. Induction of the downstream transcription of Wnt target genes, for example:

  • oncogenes such as c-Myc and cyclin D1 involved in cell cycle control [96]
  • MMP-7 and uPA, associated with metastasis and the invasion of cancer cells [86]

ANIMATION: Wnt signaling - on and off states

Tumour Cells

In a tumour cell, the Wnt signalling pathway is activated aberrantly either:

  • Inappropriately by an extracellular Wnt signal
  • In the absence of an extracellular Wnt signal
    • Usually results from a mutation in one of the subunits that comprise the “destruction complex”, resulting in an inability to degrade cytosolic β-catenin [96]
    • Mutant APC proteins characteristic of those associated with cancer, have been shown to upregulate transcription of Wnt target genes due to an inability to regulate levels of cytosolic and nuclear β-catenin [14]

MOVIE: A detailed explanation of Wnt/β-catenin signalling

Abnormal Function: Diseases associated with Wnt/β-catenin signalling

As described above, the Wnt/β-catenin signalling pathway plays a critical role in development, stem cell regulation and cellular processes such as proliferation and migration. Thus mutations in components of this pathway have been associated with cancers, hereditary disorders, developmental defects and other diseases. In addition, overexpression or underexpression of Wnt responsive genes have also been implicated in cardiovascular disorders such as hypertrophy and myocardial infarction, bone diseases and skin disorders[97][98].

Figure 6. The colon of a patient with Familial Adenomatous Polyposis (FAP)

For a comprehensive list of the range of diseases caused by mutations in Wnt-β-catenin components, please refer to Table 1 in Bryan T MacDonald, Keiko Tamai, Xi He Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell: 2009, 17(1);9-26[88]

Wnt/β-catenin Pathway and the Onset of Cancer

The high number of repressor genes involved in the Wnt/β-catenin pathway indicates that it is imperative for this pathway to be tightly regulated. [99] These repressor genes include APC, Axin 1 and Axin 2. Given the pathways involvements in the regulation of stem cell choice to proliferate or self renew, there is a strong correlation between mutations in these genes and the onset of cancer. The table below describes in further detail some mutations of the Wnt signalling pathway and associated cancers.

Mutations of the Wnt signalling pathway and associated cancers

Gene Normal function Mutation Effects of mutation Associated cancers [39]
β-catenin Primary Wnt effector. In the nucleus, β-catenin functions as a cofactor for TCF transcription factors which specify a subset of genes, which are responsible for determining cell fate and regulation of proliferation. [39] GOF mutation Any mutations that inhibit its destruction motif would cause constitutively active β-catenin signalling, leading to excessive stem cell renewal and proliferation thus predisposing the cells to the formation of tumours. [99]
  • Colorectal cancer
  • Prostate cancer
  • Uterine endometrial cancer
  • Melanoma
  • Hepatoblastoma (liver cancer)
  • Medulloblastoma (brain cancer)
  • Pancreatoblastoma (pancreatic cancer)
  • Ovarian carcinoma
  • Thyroid carcinoma
  • Pancreatic carcinoma
  • Hepatocellular carcinoma
  • Lung adenocarcinomas
  • Esophageal adenocarcinomas
  • Synovial sarcoma
APC Facilitates β-catenin degradation; acts as a tumour suppressor LOF mutation Mutational inactivation of APC inhibits the degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. [100] (See β-catenin above).


Colorectal Cancer (CRC)

  • LOF APC mutations in intestinal epithelial cells lead to constitutive β-catenin/Tcf4 complex activation, causing unrestrained production of crypt stem cells, resulting in cancer. [101] Once the cancer has spread widely through the body, it is often incurable and management focuses on chemotherapy and improving quality of life.
  • Activating mutations in the canonical Wnt pathway is responsible for approximately 90% of all colorectal cancer cases. [88] Of these, 85% are caused by loss of function mutations in APC. [39]
  • Colorectal cancer is the fourth most commonly diagnosed cancer in the world.


  • Colorectal cancer
  • Prostate cancer
  • Melanoma
  • Hepatoblastoma
  • Medulloblastoma
  • Ovarian carcinoma
  • Pancreatic non-ductal acinar cell carcinomas
  • Synovial carcinoma
  • Desmoid tumor
  • Gastric adenoma
  • Breast fibromatoses
  • Familial Adenomatous Polyposis (FAP) [Figure 6]
Axin 1 & Axin 2 Serve as scaffolding components for the β-catenin degradation complex. Acts as a tumour suppressor. LOF mutation Mutational inactivation of Axin 1 or Axin 2 inhibits the degradation of β-catenin, leading to the over-stabilisation and accumulation of β-catenin in the nucleus of the cell. (See β-catenin above).
  • Ovarian carcinoma
  • Hepatocellular carcinoma
  • Medulloblastoma
  • Predisposition to colon cancer [102]

Current research

Current Research on Inhibitors to Treat or Prevent Proliferation of Cancer

There is a large focus on finding more effective means of treating and preventing cancer. Current researchers are looking at inhibiting various components of the Wnt/β-catenin pathway to prevent the proliferation of cancer. Such treatments include:

  1. Small molecule inhibitors can be used to block the interaction between β-catenin and TCF, thus preventing constitutive transcriptional activities that lead to the proliferation of cancer. [88]
  2. Non-steroidal anti-inflammatory drugs (NSAIDs) function by interfering with β-catenin/TFC-dependent transcription, and have proven promising for the treatment and prevention of colorectal cancers. [88] Examples of NSAIDs include exisulind, sulindac and aspirin.[100] The use of NSAIDs was proven effective with a "40-50% reduction in mortality due to CRC in individuals taking NSAIDs".[88] Furthermore, studies are being conducted into the use of NSAIDs to inhibit cyclooxygenase-2 (COX-2) as an effective method of treatment and prevention of cancers. [88]
  3. Frizzled-related proteins can be used as natural antagonists to manage the Wnt pathway.
  4. A “recombinant adenovirus (Ad-CBR) that constitutively expresses the β-catenin binding domain of APC” [103] was developed, enabling APC to maintain its function of β-catenin degradation.
  5. Monoclonal antibodies are being used against Wnt proteins by inducing apoptosis in cancer cells [103].

Other Areas of Current Research

There are a multitude of research groups investigating an array of components making up the Wnt signalling pathway. Four articles most relevant in the context of this wiki page are listed below.

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling[104]

De Lau et al (2011) demonstrated that the stem cell markers Lgr5 and Lgr4 are often co-expressed in Wnt-driven cellular proliferation, where they associate with the FZ/LRP Wnt receptor complex. This is of particular importance as the deletion of both the Lgr5 and Lgr4 genes results in decreased proliferation of cells in Wnt-driven compartments (e.g. intestinal crypts in a mouse model), a result similar to the mechanism of the Wnt signalling pathway in its “OFF” state.

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling

Figure 7: Western blot results A. This panel confirms that the absence of protein in knockout cells B. LRP5 response is weaker despite having two alleles in the absence of LRP-6, indicating how the majority of signal transduction is mediated through LRP-6

Dissecting Molecular Differences between Wnt Coreceptors LRP-5 and LRP-6[105]

The current understanding of the Wnt signalling pathway is that the LRP-5/6 co-receptor plays a critical role in the transduction of signals concerning processes such as skeletal remodelling, osteoporosis pathogenesis and cancer formation. MacDonald et al (2011), expand on the canonical understanding of the pathway by differentiating between the LRP-5 and LRP-6 co-receptors and the individual processes they are responsible for. By investigating the molecular basis for these differences, it has been demonstrated that the LRP-6 coreceptor plays a predominant role in embryogenesis and also exhibits a stronger signalling activity in vivo than the LRP-5 isotype (as depicted in Figure 7).

Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6

Identification of a novel inhibitor of the canonical Wnt pathway[106]

Because of the vital role Wnt signalling plays in processes such as inflammation, angiogenesis and fibrosis; the identification of a novel inhibitor of the pathway could provide a viable therapeutic intervention for diseases characterised by excessive activation of these processes. One such inhibitor showing promise is pigment epithelium-derived factor (PEDF), which has been demonstrated to attenuate Wnt signalling induced by conditions such as retinal ischaemia. This is believed to be a result of a physical interaction between PEDF and the LRP-6 co-receptor, which blocks initiation of the pathway by preventing activation of the FZ receptor.

Identification of a Novel Inhibitor of the Canonical Wnt Pathway

Inhibition of GSK3 by Wnt signalling - two contrasting models[107]

We have discussed the role of GSK-3β in the phosphorylation of β-catenin and subsequent ubiquitylation and proteosomal degradation of the protein (“off” state), although the mechanism by which Wnt activation inhibits these events (“on state”) is unclear. This is an important step because by blocking the phosphorylation of β-catenin, the protein is able to accumulate in the cytoplasm and carry out its biological function by promoting the transcription of Wnt target genes. Metcalfe and Bienz (2011) investigated two models proposing contrasting mechanisms by which GSK-3β is inhibited by Wnt activation. The first model proposed that Wnt induces the phosphorylation of LRP-6, which consequently inhibits the catalytic activity of GSK-3β, thereby preventing phosphorylation of β-catenin. The second model suggested that Wnt signalling induces the uptake of GSK-3β in vesicles called multivesicular bodies (MVBs), and therefore prevents any interaction between the enzyme and its substrate, β-catenin. The study also tested whether either of the models have any inclination to predominate in an acute vs. chronic setting of Wnt signalling.

Inhibition of GSK3 by Wnt signalling – two contrasting models

Future directions

Although the Wnt/β-catenin signalling pathway has been well-established, there are many aspects that add complexity to this signal transduction pathway. The journal articles below are examples of areas of Wnt signalling that could potentially be investigated in the future.

The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review. [108]

This review article highlights the importance of the Wnt/β-catenin pathway to the pathogenesis of oral carcinogenesis. What is still poorly understood in the quest for a cure is the role, if any, of Wnt/β-catenin signalling in apoptosis, a crucial mode of combatting abnormal cell proliferation. Although much has been established in the mechanism of action of the canonical pathway, this topic of research is also relevant to developing treatments for many other diseases that are impacted by abnormalities in the apoptotic function of cells, and hence the continued interest in such research.

The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review

Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. [109]

Chen et al. have demonstrated the necessity of secreted Wnt ligands in not only fibroblast precursors, but also for the proliferation of fibroblasts, leading to thickening of the dermis, as well as hair follicles. However, the mechanism of the involvement of the secreted Wnt ligands in dermal fbroblast proliferation is yet to be defined, still resting on the determination of which broadly expressed Wnt ligands are required for dermal β-catenin activity, as well as what role (if any) dermal cell density plays in hair follicle formation. Elucidating such interactions pose implications for addressing diseases such as congenital human focal dermal hypoplasia and skin fibrosis.

Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation

Glossary

List of Abbreviations Used

  • APC: adenomatous polyposis coli
  • CAMKII: Ca2+/calmodulin-dependent protein kinase II
  • CK-I: casein kinase I
  • CRD: cysteine rich domain
  • CRM1: exportin-1 protein
  • DIX: dishevelled and axin domain
  • Dsh: Dishevelled
  • Fz: Frizzled
  • GOF: gain of function mutation
  • GSK-3β: glycogen synthase kinase-3β
  • HMG: high mobility group
  • LEF: lymphoid enhancer-binding factor
  • LMB: leptomycin B
  • LOF: loss of function mutation
  • LRP: lipoprotein receptor–related protein
  • MVB: multi-vesicular body
  • NES: leucine-rich nuclear export signal protein
  • Nkd: naked cuticle
  • NSAIDs: non-steroidal anti-inflammatory drugs
  • PEDF: pigment epithelium-derived factor
  • PKC: protein kinase C
  • SAMP: Ser-Ala-Met-Pro repeated amino acid segment
  • Stbm: strabismus
  • TCF: T cell factor

List of Terminology

  • Agenesis: the inability to form an organ during embryogenesis due to the lack of primordial tissues
  • Agonist: a molecule which binds to a receptor to produce a physiological response
  • Antagonist: a molecule which inhibits the physiological function of another substance
  • Apoptosis: programmed cell death
  • C-terminus: the end of the polypeptide chain which features a free carboxyl group (-COOH)
  • Canonical: standard and well accepted
  • Caveolin: integral membrane proteins involved in receptor mediated endocytosis
  • Destruction motif: short sequences which provide stability of other proteins when deleted or mutated
  • Differentiation: the process by which cells become mature and specialised in structure and function
  • Disulfide bonds: a covalent bond between sulfur atoms
  • Gain of function mutation: mutation produces a protein which has an enhanced or abnormal function
  • Glycolipoprotein: a protein with attached lipid and carbohydrate groups
  • Histone deacetylation: the process by which histone deacetylase removes acetyl groups on the histones to increase affinity and condense DNA, thus preventing transcription
  • Homeotic gene: genes involved in embryonic development, specifically controlled the anterior-posterior axis
  • Homolog: gene which is related to another gene by common descent
  • Immunohistochemistry: detecting antigens on a tissue using labelled antibodies
  • Immunoprecipitation: the process of isolating a protein antigen using an antibody that binds to it to form an insoluble complex
  • Lethal mutation: a mutation which can result in the death of the organism
  • Ligand: a molecule which binds to another entity
  • Loss of function mutation: mutation produces a protein which has decreased or no function
  • Metastasis: distant non adjacent spread of a tumour
  • Mnemonic: a tool which assists memory
  • Monoclonal antibody: an antibody engineered from a single clone of cells
  • Morphogenesis: the differentiation and growth of tissues and organs during embryo development
  • N-terminus: the start of the polypeptide chain which features a free amine group (-NH2)
  • Oncogene: genes which transform normal cells into cancerous cells
  • PDZ domain: a common structural domain of 80-90 amino acids of signalling proteins, whose name is derived from the first three letters of the first three proteins to be discovered to share the domain: post synaptic density protein, Drosophila disc large tumor suppressor, zonula occludens-1 protein
  • Pluripotency: the ability of stem cells to differentiate into ectoderm, mesoderm and endoderm
  • Proteasome: a large intracellular particle which degrades proteins
  • Repressor: a protein which binds to the operator and prevents transcription
  • Scaffolding protein: proteins which regulate signal transduction by organising and assembling signalling complexes
  • Self renewal: the capability to undergo numerous cell divisions and maintain undifferentiation
  • Sequester: to isolate or separate
  • siRNA: small interfering RNA which is involved in RNA interference
  • Synergism: the joint action of two substances which increases their effectiveness
  • Tumour suppressor gene: produces proteins which control cell growth to prevent uncontrolled cell proliferation
  • Ubiquitylation: the process of adding ubiquitin

External links

Reference List

  1. 1.0 1.1 1.2 1.3 1.4 1.5 <pubmed>17081971</pubmed>
  2. Sharma RP Wingless, a new mutant in D.melanogaster. Drosoph. Inf. Serv: 1973, 50;134
  3. <pubmed>6297757</pubmed>
  4. <pubmed>3111720</pubmed>
  5. <pubmed>2499512</pubmed>
  6. 6.0 6.1 <pubmed>2225066</pubmed>
  7. <pubmed>8259518</pubmed>
  8. <pubmed>8259519</pubmed>
  9. <pubmed>1846319</pubmed>
  10. <pubmed>1962194</pubmed>
  11. <pubmed>1989880</pubmed>
  12. <pubmed>1335365</pubmed>
  13. <pubmed>7906389</pubmed>
  14. 14.0 14.1 <pubmed>7708772</pubmed>
  15. <pubmed>8757136</pubmed>
  16. <pubmed>8717036</pubmed>
  17. <pubmed>8985181</pubmed>
  18. <pubmed>8616874</pubmed>
  19. <pubmed>9298899</pubmed>
  20. <pubmed>9233789</pubmed>
  21. <pubmed>9118221</pubmed>
  22. 22.0 22.1 <pubmed>9554852</pubmed>
  23. <pubmed>9601644</pubmed>
  24. <pubmed>10517632</pubmed>
  25. <pubmed>9920888</pubmed>
  26. <pubmed>10092233</pubmed>
  27. <pubmed>11136974</pubmed>
  28. <pubmed>11029007</pubmed>
  29. 29.0 29.1 <pubmed>11336703</pubmed>
  30. <pubmed>12660735</pubmed>
  31. <pubmed>14600025</pubmed>
  32. <pubmed>16890161</pubmed>
  33. <pubmed>17549080</pubmed>
  34. <pubmed>19001663</pubmed>
  35. <pubmed>20412773</pubmed>
  36. <pubmed>9407023</pubmed>
  37. 37.0 37.1 37.2 <pubmed>11806834</pubmed>
  38. 38.0 38.1 38.2 38.3 38.4 38.5 <pubmed>9312064</pubmed>
  39. 39.0 39.1 39.2 39.3 39.4 <pubmed>12781368</pubmed>
  40. <pubmed>9118212</pubmed>
  41. <pubmed>10201374</pubmed>
  42. <pubmed>10067895</pubmed>
  43. 43.0 43.1 43.2 <pubmed>11357136</pubmed>
  44. <pubmed>9096311</pubmed>
  45. 45.0 45.1 <pubmed>9230313</pubmed>
  46. <pubmed>11029008</pubmed>
  47. <pubmed>12050670</pubmed>
  48. <pubmed>8288125</pubmed>
  49. <pubmed>8817329</pubmed>
  50. <pubmed>9920888</pubmed>
  51. <pubmed>7744250</pubmed>
  52. <pubmed>11752446</pubmed>
  53. <pubmed>12756182</pubmed>
  54. <pubmed>11970895</pubmed>
  55. 55.0 55.1 <pubmed>11472835</pubmed>
  56. Cell Signalling Technology. (2012). Axin 1 (human). http://www.phosphosite.org/proteinAction.do?id=4768
  57. <pubmed>9920888</pubmed>
  58. 58.0 58.1 <pubmed>9482734</pubmed>
  59. <pubmed>10196136</pubmed>
  60. National Center for Biotechnology Information, U.S. National Library of Medicine. (2002). Glycogen synthase kinase-3 beta http://www.ncbi.nlm.nih.gov/protein/P49841.2
  61. <pubmed>12554650</pubmed>
  62. <pubmed>12027456</pubmed>
  63. 63.0 63.1 <pubmed>12000790</pubmed>
  64. <pubmed>8638126</pubmed>
  65. <pubmed>10428961</pubmed>
  66. <pubmed>8887544</pubmed>
  67. <pubmed>12454917</pubmed>
  68. National Center for Biotechnology Information, U.S. National Library of Medicine. Adenomatous Polyposis Coli (Xenopus laevis). http://www.ncbi.nlm.nih.gov/protein/AAB41671.1
  69. <pubmed>10811618</pubmed>
  70. <pubmed>11978510</pubmed>
  71. <pubmed>10526234</pubmed>
  72. 72.0 72.1 <pubmed>10966653</pubmed>
  73. 73.0 73.1 73.2 <pubmed>9118222</pubmed>
  74. <pubmed>11441336</pubmed>
  75. <pubmed>18682236</pubmed>
  76. <pubmed>22392999</pubmed>
  77. <pubmed>14695885</pubmed>
  78. <pubmed>12817748</pubmed>
  79. <pubmed>11956231</pubmed>
  80. <pubmed>12372345</pubmed>
  81. 81.0 81.1 <pubmed>12372345</pubmed>
  82. <pubmed>19737646</pubmed>
  83. <pubmed>15797385</pubmed>
  84. 84.0 84.1 84.2 <pubmed>7790378</pubmed>
  85. <pubmed>21173432</pubmed>
  86. 86.0 86.1 <pubmed>22550094</pubmed>
  87. <pubmed>18708403</pubmed>
  88. 88.0 88.1 88.2 88.3 88.4 88.5 88.6 88.7 <pubmed>19619488</pubmed>
  89. <pubmed>11955436</pubmed>
  90. <pubmed>15084453</pubmed>
  91. <pubmed>20676368</pubmed>
  92. <pubmed>10737769</pubmed>
  93. <pubmed>19279722</pubmed>
  94. <pubmed>17529994</pubmed>
  95. <pubmed>19460168</pubmed>
  96. 96.0 96.1 <pubmed>22466651</pubmed>
  97. <pubmed>17211410</pubmed>
  98. <pubmed>16944325</pubmed>
  99. 99.0 99.1 <pubmed>15054482</pubmed>
  100. 100.0 100.1 <pubmed>15372092</pubmed>
  101. <pubmed>22234609</pubmed>
  102. <pubmed>15042511</pubmed>
  103. 103.0 103.1 <pubmed>15578921</pubmed>
  104. <pubmed>21727895</pubmed>
  105. <pubmed>21887268</pubmed>
  106. <pubmed>21576363</pubmed>
  107. <pubmed>22083140</pubmed>
  108. <pubmed>22399606</pubmed>
  109. <pubmed>22434869 </pubmed>